Page last updated: 2024-08-25

sofosbuvir and ribavirin

sofosbuvir has been researched along with ribavirin in 791 studies

Research

Studies (791)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's632 (79.90)24.3611
2020's159 (20.10)2.80

Authors

AuthorsStudies
Abe, H; Andrei, G; Balzarini, J; Haraguchi, K; Hotta, K; Kaneda, R; Kato, N; Kitagawa, Y; Miyaike, T; Mori, K; Shimada, H; Shuto, S; Snoeck, R; Tanaka, H; Ueda, Y1
Bernatchez, JA; Li, J; Li, R; Luan, Y; Siqueira-Neto, JL; Tran, LT1
Cen, S; Chen, J; Jiang, X; Jiang, Z; Jin, J; Li, J; Li, Y; Li, Z; Peng, Z; Quan, Y; Tan, J; Wang, Y1
Boccuto, A; Botta, M; Brai, A; Dreassi, E; Garbelli, A; Maga, G; Marchi, S; Monti, M; Montomoli, E; Nola, EM; Pollutri, A; Riva, V; Saladini, F; Trivisani, CI; Trombetta, CM; Vicenti, I; Zazzi, M1
Boccuto, A; Crespan, E; De Angelis, M; Decroly, E; Dragoni, F; Eydoux, C; Giavarini, G; Maga, G; Marchi, S; Martina, MG; Montomoli, E; Nencioni, L; Radi, M; Trombetta, CM; Vicenti, I; Zazzi, M1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Chee, GM; Poordad, F1
Mangia, A; Mottola, L1
Dieterich, DT; Martel-Laferrière, V1
Albanis, E; Berrey, MM; Cornpropst, MT; Dejesus, E; Hebner, CM; Jiang, D; Kowdley, KV; Lalezari, J; Lawitz, E; Mader, M; McHutchison, JG; Nelson, DR; Rodriguez-Torres, M; Symonds, WT1
Berrey, MM; Ding, X; Gane, EJ; Hindes, RG; Hyland, RH; Stedman, CA; Svarovskaia, E; Symonds, WT1
Cornberg, M; Manns, MP1
Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT1
Burney, T; Dusheiko, G1
Afdhal, N; Albanis, E; An, D; Anderson, JK; Bernstein, DE; Berrey, MM; Crespo, I; Davis, MN; DeMicco, M; Dvory-Sobol, H; Gordon, SC; Hassanein, T; Hindes, RG; Hyland, RH; Jacobson, IM; Kowdley, KV; Lawitz, E; Nelson, DR; Symonds, WT; Vierling, JM1
Drenth, JP2
Al-Assi, MT; An, D; Bennett, M; Brainard, D; Everson, G; Feld, J; Gordon, SC; Jacobson, IM; Kowdley, KV; Lawitz, E; Lin, M; McHutchison, JG; McNally, J; Nelson, DR; Patel, K; Pianko, S; Rodriguez-Torres, M; Schiff, E; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Symonds, WT; Yoshida, EM1
Arterburn, S; Brainard, D; Davis, MN; Gane, EJ; Gordon, SC; Hassanein, T; Hyland, RH; Jacobson, IM; Jiang, D; Kayali, Z; Kowdley, KV; Lawitz, E; Mangia, A; McHutchison, JG; McNally, J; Nyberg, L; Reddy, KR; Rodriguez-Torres, M; Schultz, M; Sheikh, AM; Subramanian, GM; Symonds, WT; Wyles, D; Younossi, Z1
Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X1
Flisiak, R; Jaroszewicz, J; Parfieniuk-Kowerda, A1
Baronas, V; Haines, K; Klumpp, K; Le Pogam, S; Li, L; Nájera, I; Piso, K; So, SS; Tong, X; Yan, JM1
Ding, X; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Mo, H; Pang, PS; Poordad, FF; Symonds, WT1
Doyle, JS; Hellard, ME1
Rodríguez-Torres, M1
Gane, E; Gerber, L; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM1
Gane, E; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM1
Bon, D; Herrmann, E; Kottilil, S; Masur, H; Meissner, EG; O'Brien, TR; Osinusi, A; Prokunina-Olsson, L; Tang, W1
Corouge, M; Pol, S; Vallet-Pichard, A1
Asselah, T; Halfon, P; Marcellin, P; Schinazi, R1
Benhamou, Y; Shiffman, ML1
Traynor, K2
Koff, RS1
Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B1
Eley, T; Everson, GT; Gao, M; Gardiner, DF; Grasela, DM; Hassanein, T; Hernandez, D; Hindes, R; Hinestrosa, F; Huang, SP; Jacobson, I; Lawitz, E; Lok, AS; McPhee, F; Nelson, DR; Pasquinelli, C; Reddy, KR; Rodriguez-Torres, M; Schwartz, H; Sherman, D; Sulkowski, MS; Symonds, W; Thuluvath, PJ; Wind-Rotolo, M1
Shiffman, ML1
Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N1
Hagan, LM; Schinazi, RF; Sulkowski, MS1
Gane, E; Hunt, SL; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM1
Dusheiko, G; Esteban, R; Hezode, C; Hunt, SL; Nader, F; Reesink, HW; Stepanova, M; Weiland, O; Younossi, ZM; Zeuzem, S1
An, D; Bernstein, DE; Chojkier, M; Di Bisceglie, AM; Fried, MW; Ghalib, R; Gordon, SC; Herring, R; Hyland, RH; Kowdley, KV; Lawitz, E; McHutchison, JG; Muir, AJ; Pang, PS; Pockros, PJ; Pound, D; Reddy, KR; Rossaro, L; Rustgi, V; Ryan, M; Schiff, E; Shiffman, ML; Subramanian, GM; Svarovskaia, E; Symonds, WT1
Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M1
Afdhal, N; Agarwal, K; Bräu, N; Buggisch, P; Buti, M; Chojkier, M; Ding, X; Foster, GR; Gitlin, N; Jacobson, IM; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Mo, H; Muir, AJ; Pang, PS; Puoti, M; Romero-Gomez, M; Subramanian, GM; Symonds, WT; Yang, JC; Zarski, JP; Zeuzem, S1
Muir, AJ1
Abraham, GM; Spooner, LM2
Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A1
Grewal, P; Kim, B; Thung, SN; Trivedi, A1
Brainard, DM; Dusheiko, GM; Esteban, R; Ferenci, P; Flisiak, R; Hézode, C; Hyland, RH; Illeperuma, A; Mangia, A; McHutchison, JG; Reesink, HW; Salupere, R; Subramanian, GM; Svarovskaia, E; Symonds, WT; Weiland, O; Zeuzem, S1
Linas, BP; Pho, MT1
Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E1
Chan, J1
Alexander, P; James, A; Long, AG; Shiffman, ML1
Rice, CM; Saeed, M1
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E1
Einecke, D1
Burki, T1
Bon, D; Fauci, AS; Herrmann, E; Hewitt, S; Kottilil, S; Masur, H; McHutchison, J; Meissner, EG; Osinusi, A; Polis, M; Porcella, S; Prokunina-Olsson, L; Sturdevant, D; Suffredini, AF; Virtaneva, K; Wang, H; Wu, D1
Chung, RT; Feeney, ER1
Bourhis, F; Cure, S; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM1
Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z1
Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P1
Beumont, M; Callewaert, K; Corregidor, A; DeJesus, E; Fevery, B; Ghalib, R; Gitlin, N; Jacobson, IM; Lambrecht, T; Lawitz, E; Lim, JK; Lindsay, KL; Ouwerkerk-Mahadevan, S; Pearlman, B; Picchio, G; Pockros, PJ; Rabinovitz, M; Rodriguez-Torres, M; Scott, JD; Sulkowski, MS; Symonds, WT; Younossi, ZM1
Brainard, D; Chodavarapu, K; Crespo Garcia, J; De Knegt, R; Doehle, B; Drenth, JP; Gontcharova, V; Hedskog, C; McHutchison, JG; Miller, MD; Mo, H; Stamm, LM; Svarovskaia, E1
Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C1
Bureau, C; Danjoux, M; Delabaudière, C; Dörr, G; Izopet, J; Kamar, N; Lavayssière, L; Muscari, F; Peron, JM; Rostaing, L; Sallusto, F1
Price, JC; Terrault, NA1
Brainard, D; Dvory-Sobol, H; Gao, B; Garrison, KL; Genda, T; Hino, K; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, S; McHutchison, JG; Mizokami, M; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Nishiguchi, S; Omata, M; Omote, M; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O1
Kottilil, S; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Naggie, S; Osinusi, A; Patel, K; Qin, J; Remaley, AT; Sampson, M; Sims, Z; Sturdevant, D; Subramanian, M1
Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA1
Foster, GR2
De Silva, S; Foster, GR1
Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA1
Dillon, JF; Miller, MH; Paterson, JC1
An, D; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Poordad, F; Symonds, WT1
Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Watcha, D1
Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA1
Alqahtani, SA; Dhingra, A; Kapoor, S1
Rojas, Á; Romero-Gómez, M1
Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X1
Firpi, RJ; Hilgenfeldt, E1
Cornberg, M; Höner zu Siederdissen, C1
Charlton, MR; Gallegos-Orozco, JF1
Feray, C; Hézode, C; Pawlotsky, JM; Ruiz, I1
Ferenci, P1
Ain, D; Doehle, B; Jiang, D; Kersey, K; Kirby, BJ; Knox, SJ; Massetto, B; McHutchison, JG; Meshrekey, R; Mikhail, S; Riad, J; Ruane, PJ; Soliman, M; Stryker, R; Symonds, WT; Wolfe, PR1
Aghemo, A; Donato, MF1
Mangia, A; Piazzolla, V1
Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS1
Chan, J; Mohammad, RA; Smith, MA1
Bodeau, S; Brochot, E; Duverlie, G1
Jensen, DM; Welch, NM1
Serfaty, L1
Ansaldi, C; Benali, S; Bourlière, M; Le Folgoc, G; Lecomte, L; Riso, A1
Abdel-Razek, W; Waked, I1
Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Maasoumy, B; Manns, MP; Mix, C; Port, K; Sollik, L; Wedemeyer, H1
Baumert, TF; Brainard, D; Brandt-Sarif, T; Castells, L; Chang, P; Charlton, M; Coilly, A; Denning, J; Fontana, RJ; Forns, X; Habersetzer, F; Kivett, V; Londoño, MC; McHutchison, JG; Prieto, M; Symonds, WT1
Ehleben, C; Pearlman, BL; Perrys, M1
Hunt, SL; Naggie, S; Orkin, C; Puoti, M; Stepanova, M; Sulkowski, M; Younossi, ZM1
Abbott, S; Barrett, LL; Bon, D; Chavez, J; Diaz, G; Egerson, D; Fauci, AS; Gross, C; Herrmann, E; Jolley, TA; Kapoor, R; Kleiner, DE; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Marti, MM; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Petersen, T; Polis, MA; Proschan, M; Sidharthan, S; Silk, R; Sims, Z; Sneller, M; Spurlin, E; Subramanian, GM; Symonds, WT; Talwani, R; Teferi, G; Townsend, K; Wood, BJ1
Childs-Kean, LM; Hand, EO1
Ahmed, A; Dieterich, D; Gordon, SC; Park, H; Saab, S; Younossi, ZM2
Carey, L1
Brainard, D; Gaggar, A; Gonzalez, M; Kirby, B; McHutchison, JG; Rodriguez-Orengo, J; Rodriguez-Torres, M; Shen, G; Svarovskaia, E; Symonds, WT1
Denk, G; Eberle, J; Guba, M; Kaspar, M; Kolligs, F; Pichler, M; Seybold, U; Spannagl, M; Stemberger, M1
Afdhal, N; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S1
Brainard, D; Gaggar, A; Iser, DM; Massetto, B; McHutchison, JG; Molina, JM; Nelson, M; Ni, L; Orkin, C; Puoti, M; Rockstroh, JK; Stephan, C; Subramanian, GM; Svarovskaia, E; Zamora, FX1
Kim, AY; Naggie, S1
Aqel, B; Chervenak, AE; Henry, TM; Keaveny, AP; Leise, M; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT1
Füessl, HS1
Jäger-Becker, D1
Asselah, T1
Abergel, A; Alric, L; Bourlière, M; Bronowicki, JP; de Ledinghen, V; Doehle, B; Grangé, JD; Guyader, D; Habersetzer, F; Hézode, C; Hyland, RH; Jiang, D; Larrey, DG; Leroy, V; Loustaud-Ratti, V; Marcellin, P; Mathurin, P; McHutchison, JG; Metivier, S; Pang, PS; Pol, S; Ratziu, V; Serfaty, L; Subramanian, GM; Symonds, WT; Tran, A; Zoulim, F1
Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH1
Liffmann, DK; Rein, DB; Smith, BD; Ward, JW; Wittenborn, JS1
Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC1
Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D1
Ji, J; Liu, D; Michailidis, E; Ndongwe, TP; Ralston, R; Rice, CM; Sarafianos, SG1
Flamm, S; Lawitz, E; McHutchison, JG; Morelli, G; Pang, PS; Pockros, P; Svarovskaia, E; Wyles, D; Yang, JC; Younes, Z; Zhu, Y1
Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S1
Bennett, M; Brainard, D; Doehle, B; Gane, EJ; Hassanein, T; Jacobson, IM; Kanwar, B; Liu, L; McHutchison, JG; Mo, H; Nahass, RG; Pol, S; Subramanian, GM; Sulkowski, MS; Symonds, WT1
Brault, P; Klotz, C; Mallet, V; Pol, S; Sultanik, P1
Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O1
Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M1
Chtioui, H; Decosterd, LA; Giostra, E; Majno, PE; Moradpour, D; Pascual, M; Vionnet, J1
Cammà, C; Carosi, G; Craxì, A; Cure, S; Guerra, I1
Doehle, B; Doss, W; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Jiang, D; Kersey, K; Khairy, M; Knox, SJ; Massetto, B; McHutchison, JG; Samir, W; Shiha, G; Soliman, R1
Colombo, M1
Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S1
Beebe, A; Gicquelais, RE; Haselow, DT; Patil, N; Quattlebaum, T; Smith, NH; Zohoori, N1
Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M1
Bushman, LR; Jimmerson, LC; Kiser, JJ; Kottilil, S; McHutchison, JG; Meissner, EG; Osinusi, A; Petersen, T; Rower, JE; Sims, Z; Wolfe, P1
Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD1
Feld, JJ; Shah, H; Sheehan, K; Sockalingam, S1
Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B1
Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C1
Hunt, S; Lam, B; Nader, F; Stepanova, M; Younossi, ZM1
Bourlière, M; Bronowicki, JP; Carrieri, MP; Pol, S; Stepanova, M; Younossi, ZM1
Baldelli, S; Cattaneo, D; Gervasoni, C; Milazzo, L; Peri, AM; Rizzardini, G1
Buggisch, P; Eißing, C; Hartl, J; Jordan, S; Lohse, AW; Lüth, S; Petersen, J; Schulze Zur Wiesch, J; Stoehr, A; Wehmeyer, MH1
Aqel, BA; Chervenak, AE; Keaveny, AP; Leise, M; McLemore, R; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT1
Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA2
Dusheiko, G; Kalafateli, M; Manousou, P1
Aristizabal, P; Carlin, AF; Paulson, MS; Schooley, RT; Song, Q; Stamm, LM; Wang, H; Wyles, DL1
Bau, S; Busuttil, RW; Durazo, F; El Kabany, M; Goo, T; Han, S; Jimenez, M; Kaldas, F; Saab, S; Tong, MJ; Zhao, D1
Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F1
Beinhardt, S; Ferenci, P; Ferlitsch, A; Freissmuth, C; Hofer, H; Kozbial, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Schwarzer, R; Stättermayer, AF; Trauner, M1
Albert, ML; Casrouge, A; Decalf, J; Duffy, D; Kottilil, S; Masur, H; Meissner, EG1
Ballestri, S; Bertolotti, M; Lonardo, A; Marrazzo, A; Romagnoli, D1
Alexander, PC; James, AM; Long, AG; Shiffman, ML1
Gissel, C; Götz, G; Mahlich, J; Repp, H1
Bastian, ND; Griffin, PM; Zhang, S1
Antoni, C; Eisenbach, C; Galle, PR; Pathil, A; Schattenberg, JM; Sprinzl, MF; Stein, K; Steinebrunner, N; Stremmel, W; Wörns, MA; Zimmerer, T; Zimmermann, T1
Escheik, C; Estep, M; Gerber, L; Stepanova, M; Weinstein, A; Younossi, ZM1
Agarwal, K; Barnes, E; Brainard, DM; Brown, A; Cooper, C; Forton, D; Foster, GR; George, J; Han, B; Lin, M; Massetto, B; McHutchison, JG; Nahass, RG; Pianko, S; Subramanian, GM1
Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Manns, MP; Mix, C; Mix, H; Port, K; Solbach, P; Sollik, L; Wedemeyer, H; Worzala, D1
An, D; Brainard, D; Gane, EJ; Hyland, RH; Pang, PS; Stedman, CA; Svarovskaia, E1
Brainard, DM; Elsheikh, E; Gerber, L; McHutchinson, JG; Nader, F; Stamm, LM; Stepanova, M; Younossi, ZM1
Aghemo, A; Bruno, R1
Buti, M; Esteban, R; Riveiro-Barciela, M1
Alavi, M; Day, R; Dore, GJ; Martinello, M; Matthews, GV; Schteinman, A; Williams, K1
Aldersley, MA; Dyson, JK; Foster, GR; Harrison, L; Hutchinson, J; McPherson, S; Rotimi, O; Tiniakos, D1
Barnes, M; Gautam, M; Gonzalez, S; Habib, A; Mantry, P; McAfee, J; Modi, AA; Nazario, H; Teachenor, O; Trotter, JF; Tujague, L; Weinstein, J1
Brainard, DM; Clark, PJ; Estep, M; Hunt, S; McHutchison, JG; Negro, F; Patel, K; Paulson, M; Song, Q; Stamm, LM; Stepanova, M; Subramanian, GM; Younossi, ZM1
Gan, D; Hu, AR; Lou, J; Shi, X; Zhu, B; Zhu, D1
Chung, RT; Corey, KE; Friedman, LS; Hundemer, GL; Sise, ME; Ufere, N; Wisocky, J1
Farfour, E; Hillaire, S; Kahn, JE; Peytavin, G; Sené, T; Zucman, D1
Kalsekar, A; Kelley, C; Kim, S; Mu, F; Noviello, S; Signorovitch, J; Song, J; Swallow, E; Yuan, Y1
Beckebaum, S; Bester, C; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL; Stahl, M; Vorona, E1
Dao Thi, VL; Debing, Y; Gouttenoire, J; Moradpour, D; Neyts, J; Rice, CM; Wu, X1
Bronowicki, JP; Hézode, C1
Buti, M; Esteban, R2
Wyles, DL1
Aggarwal, A; Ahmed, A; Chao, DT; Jayasekera, CR; Perumpail, RB; Pham, EA; Wong, RJ1
Bloom, AK; Chung, RT; Gustafson, JL; Hashemi, N; Kim, AY; Lin, MV; Lundquist, AL; Sise, ME; Steele, D; Thadhani, R; Thiim, M; Williams, WW; Wisocky, J1
Calabuig, M; Hernández-Boluda, JC; Navarro, D; Piñana, JL; Serra, MÁ; Solano, C1
Jordan, S; Lang, M; Lohse, AW; Nashan, B; Pischke, S; Polywka, S; Proske, VM; Sterneck, M1
Brown, RS; Darling, JM; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Jacobson, IM; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Reddy, KR; Stewart, TG; Sulkowski, MS; Vargas, HE1
Brainard, DM; Chan, HL; Han, LL; Knox, SJ; Lai, CL; Mo, H; Wong, VW; Yang, JC; Yuen, MF1
Brainard, DM; Doehle, B; Dore, GJ; Flamm, SL; Gane, EJ; Han, L; Kumar, S; McHutchison, JG; McNally, J; Mogalian, E; Pianko, S; Rabinovitz, M; Reddy, KR; Roberts, SK; Shiffman, ML; Stedman, CA; Strasser, SI; Towner, WJ1
Kattakuzhy, S; Kottilil, S; Tang, L; Ward, H; Wilson, E1
Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K1
Alric, L; Cacoub, P; Costopoulos, M; Fontaine, H; Guillaud, C; Hezode, C; Izzedine, H; Le Garff-Tavernier, M; Mallet, M; Musset, L; Plaisier, A; Pol, S; Poynard, T; Saadoun, D; Si Ahmed, SN; Thibault, V1
An, D; Brainard, DM; Brown, RS; Bzowej, N; Charlton, M; Curry, MP; Doehle, B; Fenkel, JM; Flamm, SL; Fontana, R; Fried, M; Korenblat, KM; Lawitz, E; McHutchison, JG; McNally, J; Muir, AJ; O'Leary, JG; Osinusi, A; Reddy, KR; Schiano, T; Schiff, E; Teperman, L1
Adhoute, X; Ansaldi, C; Benali, S; Bourlière, M; Castellani, P; Halfon, P; Oules, V; Portal, I1
Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P2
Gish, R; Kohli, A; Manch, R; Nafisi, S; Roy, S1
Farnik, H; Herrmann, E; Lange, CM; Luhne, S; Sarrazin, C; Vermehren, J; Welker, MW; Welzel, T; Zeuzem, S1
Burger, J; Dranitsaris, G; Fraser, I; Lubbe, M; Sonderup, M; Stander, T1
Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y1
Luo, R; Nong, J; Qing, J; Shao, Y; Sun, Y; Tang, R; Wang, Y; Wu, M; Yin, Z; Yu, X1
Nelson, DR; Peter, J1
Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ1
Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R1
Craft, ZN; Kamal, KM; Koerner, PH; Miller, RT; Trombatt, WD1
Salman, AG1
Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ1
Arleo, A; Copetti, M; Mangia, A; Miscio, M; Piazzolla, V; Santoro, R; Squillante, MM1
Hoofnagle, JH1
Rivero, A; Rivero-Juárez, A1
Angus, P; Bhore, R; Bronowicki, JP; Dore, GJ; Hezode, C; Jimenez-Exposito, MJ; Leroy, V; McPhee, F; Pianko, S; Pol, S; Stuart, K; Thompson, AJ; Tse, E1
Damha, MJ; Doehle, B; Götte, M; Kulkarni, AS; Mo, H; Sagan, SM; Schinazi, RF1
Henry, L; Nader, F; Stepanova, M; Younossi, ZM1
Cheng, N; Ford, R; Norvell, JP; Parekh, S; Pillai, AA; Spivey, JR; Wedd, J; Young, N1
Brainard, DM; Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Han, L; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mathias, A; Mo, H; Peng, CY; Sheen, IS; Wang, HY; Yang, JC1
Ackerman, P; Kalsekar, A; Kelley, C; Mu, F; Peeples, M; Signorovitch, J; Song, J; Swallow, E; Yuan, Y1
Ahn, SH; Brainard, DM; Byun, KS; Han, KH; Han, L; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mathias, A; Mo, H; Paik, SW; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK1
Chen, TM; Huang, PT; Li, YC1
Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O1
Afdhal, N; Charlton, M; Denning, J; Everson, GT; Flamm, SL; Hyland, R; Lin, M; McHutchison, JG; Pang, PS; Reddy, KR; Welzel, TM; Zeuzem, S1
Agarwal, K; Angus, P; Arterburn, S; Brainard, D; Buti, M; Calleja, JL; Colombo, M; Denning, J; Dufour, JF; Dvory-Sobol, H; Forns, X; Gane, EJ; Manns, M; McCaughan, G; McHutchison, JG; Müllhaupt, B; Mutimer, D; Pang, PS; Peck-Radosavljevic, M; Prieto, M; Rizzetto, M; Samuel, D; van Hoek, B; Van Vlierberghe, H; Yoshida, EM1
Barve, A; Brock, G; Buchanan, LA; Cave, B; Cave, MC; Crittenden, NE; Davis, EG; Gedaly, R; Jones, CM; Kuns-Adkins, CB; Marsano, L; Marvin, MR; McClain, CJ; Pinkston, CM; Rosenau, J; Shah, MB1
Gonzalez, HC; Nair, S; Satapathy, SK1
Li, CX; Li, W; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW1
Aljudaibi, B; Bilodeau, M; Congly, SE; Cooper, C; Faisal, N; Ghali, MP; Hirsch, G; Hussaini, T; Leonard, J; Lilly, LB; Ma, MM; Peltekian, K; Renner, EL; Yoshida, EM1
Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D1
Agarwal, K; Feld, J; Henry, L; Hezode, C; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Younossi, ZM; Zeuzem, S1
Benhaourech, S; Borentain, P; Bregigeon, S; Colson, P; Darque, A; Gaubert, MR; Habib, G; Laugier, D; Maille, B; Renard, S; Salaun, E1
Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R1
Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H1
Jung, YK1
Alkhouri, N; Apfel, T; Hanouneh, IA; Hanouneh, M; Jackson, WE; John, BV; Zein, NN; Zervos, X1
Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM1
Badia, E; Sáez-Royuela, F1
Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A1
Warpakowski, A1
Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA1
Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC1
Brainard, DM; Byrne, S; Copans, A; Dvory-Sobol, H; Fuchs, M; Guyer, W; Ho, SB; Kaplan, DE; Le, H; Monto, A; Moon, S; Morgan, TR; Peyton, A; Rossaro, L; Roy, A; Shaikh, O; Zhu, Y1
Cotler, SJ; Dahari, H; Halfon, P1
Neumaier, J1
Abergel, A; Anty, R; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; de Ledinghen, V; Debette-Gratien, M; Di Martino, V; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rohel, A; Roque-Afonso, AM; Rossignol, E; Samuel, D; Silvain, C1
Flemming, JA; Lowe, CE1
Afdhal, NH; Brainard, DM; Chuang, SM; Ding, X; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Ma, J; McHutchison, JG; Miller, MD; Mo, H; Pang, PS; Sarrazin, C; Svarovskaia, ES1
Ampuero, J; Reddy, KR; Romero-Gomez, M1
Brügger, U; Girardin, F; Goossens, N; Negro, F; Perrier, A; Riguzzi, M; Vernaz, N1
Biasi, L; Casari, S; Castelli, F; Chirico, C; Festa, E; Izzo, I; Salemme, M; Villanacci, V; Zanotti, P1
Alric, L; Aumaître, H; Bani-Sadr, F; Billaud, E; Bouchaud, O; Boué, F; Chas, J; Dabis, F; Dominguez, S; Esterle, L; Gervais, A; Gilbert, C; Goujard, C; Lacombe, K; Lascoux-Combe, C; Miailhes, P; Morlat, P; Neau, D; Piroth, L; Poizot-Martin, I; Rosenthal, E; Salmon, D; Simon, A; Sogni, P; Valantin, MA; Vittecoq, D; Wittkop, L; Zucman, D1
Burger, D; Gevers, TJ; Kooistra, MP; Richter, C; Schipper-Reintjes, E1
Akushevich, L; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Kuo, A; Maan, R; Mailliard, M; Manns, MP; Nelson, DR; Schmidt, M; Sherman, K; Sterling, R; Vainorius, M; Zeuzem, S1
Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A1
Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A1
Amoroso, A; Arese, D; Cocchis, D; Dell Olio, D; Magistroni, P; Martini, S; Mirabella, S; Moschini, P; Ottobrelli, A; Rizza, G; Rizzetto, M; Romagnoli, R; Sacco, M; Salizzoni, M; Saracco, GM; Stradella, D; Strona, S; Tandoi, F1
Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A1
Ross, JS; Sangaralingham, LR; Shah, ND; Talwalkar, JA; Yao, X1
Durlik, M; Hreńczuk, M; Kosieradzki, M; Małkowski, P; Pacholczyk, M; Sowińska, R; Tronina, O1
Bakulin, I; Chulanov, V; Isakov, V; Kersey, K; Knox, SJ; Massetto, B; Svarovskaia, E; Zhdanov, K; Zhu, Y1
Andreis, S; Basso, M; Cattelan, AM; Cavinato, S; Dal Bello, F; Loregian, A; Messa, L; Nannetti, G; Palù, G; Parisi, SG; Scaggiante, R1
Arai, M; Haga, Y; Kanda, T; Katsuno, T; Nakamoto, S; Nakamura, M; Ohta, Y; Sasaki, R; Wu, S; Yasui, S; Yokosuka, O1
Agüero, F; Ambrosioni, J; Costa, J; Forner, A; Laguno, M; Lligoña, A; Londoño, MC; Manzardo, C; Miró, JM; Moreno, A; Rimola, A; Ruiz, P1
Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME1
Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S1
Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, Y; Younossi, ZM1
Buggisch, P; Cornberg, M; Günther, R; John, C; Klinker, H; Lutz, T; Mauss, S; Niederau, C; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Tacke, F1
Aghemo, A; Carrinola, R; Colombo, M; D'Ambrosio, R; Rossetti, V1
Afdhal, N; Bräu, N; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; Patel, K; Reau, N; Roberts, SK; Stepanova, M; Sulkowski, M; Younossi, ZM1
Aba Alkhail, F; Ajlan, A; Al-Hamoudi, W; Al-Jedai, A; Al-Sebayel, M; Alarieh, R; Alkortas, D; Broering, D; Elsiesy, H1
Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K1
Butt, AA; Marks, K; Shaikh, OS; Sherman, KE; Yan, P1
Maasoumy, B; Sarrazin, C; Vermehren, J; Wedemeyer, H1
D'Ambrosio, R; De Nicola, S; Degasperi, E; Rumi, M1
Casato, M; Ceccotti, G; Colantuono, S; De Santis, A; Del Padre, M; Fiorilli, M; Fognani, E; Gianni, E; Gragnani, L; Mitrevski, M; Monti, M; Perez, M; Petraccia, L; Pulsoni, A; Stasi, C; Urraro, T; Visentini, M; Zignego, AL1
Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z1
Afdhal, NH; Buti, M; Curry, MP; Dufour, JF; Firdoos, S; Flamm, S; Hughes, MS; Tapper, EB1
Appolo, B; Bloom, R; Patel, N; Sawinski, D1
Bailly, F; Choupeaux, L; Gagnieu, MC; Maynard, M; Pradat, P; Scholtès, C; Virlogeux, V; Zoulim, F1
Afdhal, NH; Bacon, BR; Curry, MP; Dieterich, DT; Flamm, SL; Guest, LE; Kowdley, KV; Lee, Y; Tapper, EB; Tsai, NC; Younossi, ZM2
Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, ZM1
Asante-Appiah, E; Barr, E; Flisiak, R; Gerstoft, J; Halota, W; Horvath, G; Jancoriene, L; Kazenaite, E; Kileng, H; Koklu, S; Leiva, R; Nguyen, BY; Patel, S; Platt, HL; Prinzing, R; Qiu, J; Ruiz-Tapiador, JA; Sperl, J; Streinu-Cercel, A; Urbanek, P; Wahl, J; Werling, K1
Ahn, J; Branch, A; Gripshover, J; Hassan, MA; Kwok, RM; Lee Sang, M; Patel, N; Potosky, DR; Robertazzi, S; Rodigas, C; Satoskar, R; Schiano, TD; Smith, CI; Te, HS; Tierney, A; Wiegel, J1
Keating, GM1
Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y1
Aspinall, RJ; Brainard, DM; Dore, GJ; Feld, JJ; Foster, GR; Fox, R; Grebely, J; Han, L; Mangia, A; McNally, J; Natha, M; Osinusi, A; Subramanian, GM; Sulkowski, M; Zeuzem, S1
Akushevich, L; Ben Ari, Z; Di Bisceglie, AM; Frazier, LM; Fried, MW; Kuo, A; Lim, JK; Lok, AS; Nelson, DR; Pockros, PJ; Shiffman, ML; Sulkowski, MS; Terrault, NA; Vainorius, M; Zeuzem, S1
Drago, F; Gasparini, G; Marenco, S; Parodi, A; Picciotto, A1
Abushouk, AI; Ahmed, H; Attia, A; Elgebaly, A; Hammad, AM; Negida, A1
Berg, T; Ferenci, P; Gschwantler, M; Herzer, K; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, J; Spengler, U; van der Valk, M; Wedemeyer, H; Weiland, O; Welzel, TM; Zeuzem, S; Zhao, Y1
He, QF; Zhang, DZ; Zhang, QF1
Alric, L; Billaud, E; Bourcier, V; Bourliere, M; Bronowicki, JP; Carrat, F; Causse, X; Chazouilleres, O; D'Alteroche, L; Diallo, A; Dorival, C; Fontaine, H; Fouchard-Hubert, I; Geist, C; Gournay, J; Guyader, D; Habersetzer, F; Hezode, C; Larrey, D; Ledinghen, VD; Loustaud-Ratti, V; Lucier, S; Marcellin, P; Mathurin, P; Metivier, S; Minello, A; Petrov-Sanchez, V; Pol, S; Riachi, G; Rosa, I; Saillard, E; Samuel, D; Thabut, D; Tran, A; Zarski, JP; Zoulim, F1
Chawla, Y; Dhiman, RK; Duseja, A; Mehta, M; Satsangi, S; Taneja, S1
Abou Mrad, R; Alkhouri, N; Carey, WD; Eghtesad, B; Elfeki, MA; Hanouneh, IA; Modaresi Esfeh, J; O'Shea, R; Zein, NN; Zervos, X1
Damrah, I; Eurich, D; Gül-Klein, S; Pratschke, J; Raschzok, N; Reutzel-Selke, A; Sauer, IM; Schott, E; Stockmann, M; Strücker, B1
Furusyo, N; Hayashi, J; Hotta, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K; Uchiumi, T1
Fortune, BE; Lim, JK; McCarty, TR; Njei, B1
Kwo, PY; Liangpunsakul, S1
Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR1
Kater, AP; Schinkel, J; van der Valk, M; Zaaijer, HL1
Britnell, SR; Britt, RB; Vanderman, AJ; Willets, AE; Woodard, CL1
Greig, SL1
Beck, KR; Khalili, M; Kim, N1
Shi, KQ; Wang, BQ; Wang, YL1
Berry, K; Green, PK; Ioannou, GN; Su, F1
Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P1
Mendes, LC; Miotto, N; Stucchi, RS; Vigani, AG; Zanaga, LP1
Ardeshna, K; Maciocia, N; O'Brien, A1
Assis Jarek, NA; Borba, HH; Ferreira, VL; Muzzillo, DA; Pontarolo, R; Tonin, FS; Wiens, A1
Kaur, K; Mahajan, R; Mehta, V; Midha, V; Narang, V; Sharma, S; Singh, D; Sood, A; Wander, P1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K1
Akuschevich, L; Brown, RS; Di Bisceglie, AM; Everson, GT; Fried, MW; Galati, JS; Kuo, A; Kwo, PY; Lim, JK; Lok, AS; Manns, MP; Morelli, G; Nelson, DR; Pockros, PJ; Reddy, KR; Sulkowski, MS; Terrault, NA; Vainorius, M1
Moiseev, S; Mukhin, N; Novikov, P1
Gul, A; Mahmood, S; Saif, T1
Aikata, H; Amano, H; Arataki, K; Chayama, K; Hayes, CN; Hiramatsu, A; Imamura, M; Ito, H; Kawakami, Y; Kawaoka, T; Kohno, H; Makokha, GN; Morio, K; Moriya, T; Nagaoki, Y; Nakahara, T; Nakamura, T; Ochi, H; Tamura, T; Tsuge, M; Tsuji, K; Waki, K1
Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R1
Canbay, A; Gerken, G; Herzer, K; Paul, A; Timm, J; Treckmann, J; Willuweit, K1
Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S1
Ingiliz, P; Jimenez-Exposito, MJ; Peck-Radosavljevic, M; Petersen, J; Rockstroh, JK; Van der Valk, M; Welzel, TM; Zeuzem, S; Zhao, Y1
Charlton, M; Curry, MP; Feld, J; Foster, GR; Henry, L; Hunt, S; Mangia, A; Nader, F; O'Leary, JG; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S1
Elsheikh, E; Estep, JM; Gerber, L; Golabi, P; Karrar, A; Stepanova, M; Younossi, I; Younossi, ZM1
Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R1
Buti, M; Calleja, JL; Corbett, C; Crespo, J; Diago, M; Fevery, B; Jessner, W; Kalmeijer, R; Kurland, D; Lens, S; Ortega, E; Pascasio, JM; Planas, R; Rodríguez, FG; Romero-Gómez, M1
Kahn, JG; Lai, JC; Mehta, N; Roberts, JP; Salazar, J; Saxena, V; Volk, M1
Liu, H; Yan, Y; Zhang, T1
Acevedo, P; Bernal Blanco, G; Gentil Govantez, MA; Gonzalez Roncero, FM; Gonzalez-Corvillo, C; Perez Valdivia, MA; Sousa, JM; Suarez Benjumea, A; Suñer Poblet, M1
Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S1
Castells, L; Fernandez Vazquez, I; Herrero, JI; Londoño, M; Narvaez Rodriguez, I; Otero, A; Pascasio, JM; Prieto, M; Sanchez Antolin, G; Testillano, M1
Acharya, SK; Chowdhury, A; Doehle, B; Duseja, A; Jiang, D; Kanwar, B; Kapoor, D; Kersey, K; Koshy, A; Madan, K; Mehta, R; Nijhawan, S; Pawan, R; Prasad, M; Sarin, S; Shah, SR; Shukla, A; Sood, A; Subramanian, M; Sud, R; Svarovskaia, E1
Alonso, S; Ampuero, J; Badia, E; Baliellas, C; Buti, M; Carrión, JA; Castro, Á; Devesa, MJ; Esteban, R; Fernandez, I; Fernandez-Carrillo, C; Fernández-Rodríguez, CM; Gea, F; Gómez, A; Granados, R; Lens, S; Llerena, S; Montero, JL; Olveira, A; Pascasio, JM; Planas, JM; Polo, B; Real, Y; Rincón, D; Riveiro-Barciela, M; Rubín, A; Salmeron, J; Turnes, J1
Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM1
Clayton, CW; Jimmerson, LC; Kiser, JJ; Kottilil, S; MaWhinney, S; Meissner, EG; Sims, Z1
Agostinacchio, E; Arleo, A; Carraturo, I; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Miscio, M; Palmieri, V; Piazzolla, V; Potenza, D; Santoro, R; Sarrazin, C; Spinzi, G; Susser, S1
Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S1
Alberti, A; Bonfanti, M; Croce, D; Lazzarin, A; Nappi, C; Restelli, U1
Hernandez, D; McPhee, F; Zhou, N1
Berg, T; Ferenci, P; Herzer, K; Hinrichsen, H; Inderson, A; Jimenez-Exposito, MJ; Klinker, H; Peck-Radosavljevic, M; Spengler, U; Welzel, TM; Zeuzem, S; Zhao, Y1
Backstedt, D; Choi, M; Patel, A; Pedersen, MR; Seetharam, AB1
Chen, Y; Jiang, X; Song, Y; Tao, T1
Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J1
Lange, CM; Mücke, MM; Mücke, VT; Zeuzem, S1
Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P1
Bucher, HC; Calleja, JL; Castells, L; Evans, D; Giostra, E; Hofer, H; Irving, W; Lefevre, C; Pascasio, JM; Postema, R; Prieto, M; Weiland, O; Weis, N; Young, J1
Abdelaziz, AO; Doss, W; El Akel, W; El Demerdash, T; El Raziky, M; El Serafy, M; El Shazly, Y; Elsharkawy, A; Esmat, G; Fouad, R; Gaballah, A; Hassany, M; Makhlouf, MA; Motawea, I; Said, M; Seif, S; Shiha, G; Thursz, M; Waked, I; Yosry, A1
Huang, J; Liao, H; Tan, P; Yan, X; Zhu, Z1
Baldanti, F; Ludovisi, S; Mondelli, MU; Paolucci, S; Premoli, M1
Andreoni, M; Angelico, M; Antonucci, F; Aragri, M; Babudieri, S; Barbaliscia, S; Bellocchi, MC; Bertoli, A; Brancaccio, G; Calvaruso, V; Caporaso, N; Ceccherini-Silberstein, F; Cento, V; Cozzolongo, R; Craxì, A; Di Biagio, A; Di Maio, VC; Francioso, S; Gianserra, L; Grieco, A; Landonio, S; Lenci, I; Loggi, E; Magni, CF; Masetti, C; Mastroianni, CM; Melis, M; Merli, M; Micheli, V; Morisco, F; Pace Palitti, V; Paoloni, M; Parruti, G; Pasquazzi, C; Pellicelli, AM; Perno, CF; Picciotto, A; Puoti, M; Rizzardini, G; Romagnoli, D; Rossi, P; Santopaolo, F; Sarmati, L; Siciliano, M; Taliani, G; Tarquini, P; Teti, E; Vecchiet, J; Verucchi, G; Vullo, V1
Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S1
Yu, ML1
Balba, G; Bowlus, CL; Brainard, DM; Cohen, A; Fried, MW; Han, B; Hyland, RH; Kim, AY; Kouides, P; McHutchison, JG; Reddy, KR; Rhame, F; Sax, PE; Stamm, LM; Terrault, NA; von Drygalski, A; Walsh, CE; Wang, J; Workowski, K1
Bourgeois, S; de Galocsy, C; Degré, D; Delwaide, J; Geerts, A; Gustot, T; Laleman, W; Langlet, P; Lasser, L; Lepida, A; Moreno, C; Negrin Dastis, S; Orlent, H; Reynaert, H; Sersté, T; Starkel, P; Van Steenkiste, C; Vanwolleghem, T1
Akamatsu, N; Eguchi, S; Goto, R; Ikegami, T; Kitagawa, Y; Kokudo, N; Maehara, Y; Okajima, H; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yoshizumi, T1
Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, Z1
Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A1
Abe, M; Hiasa, Y; Hirooka, M; Horiike, N; Joko, K; Kisaka, Y; Michitaka, K; Nakanishi, S; Nonaka, T; Tada, F; Tanaka, Y; Tokumoto, Y; Watanabe, T; Yamauchi, K1
Albillos, A; Arenas, J; Badia, E; Baliellas, C; Blé, M; Buti, M; Calleja, JL; Carrión, JA; Castells, L; Crespo, J; de la Mata, M; Fernández Bermejo, M; Fernández Carrillo, C; Fernández, I; Fernández-Rodriguez, C; García-Samaniego, J; Granados, R; Herrero, JI; Lens, S; Llop, E; Mariño, Z; Moreno-Palomares, JJ; Moreno-Planas, JM; Pascasio, JM; Pons, C; Prieto, M; Romero, M; Salcedo, M; Salmerón, J; Turnes, J1
Akremi, R; Bennai, Y; Botta-Fridlund, D; Bourliere, M; Boyer, N; Bronowicki, JP; D'Alteroche, L; De Ledinghen, V; Di Martino, V; Fedchuk, L; Filipovics, A; Fontaine, H; Guyader, D; Hézode, C; Hubert-Fouchard, I; Larrey, D; Lebray, P; Leroy, V; Nguyen-Khac, E; Rosa, I; Silvain, C; Zhao, Y; Zoulim, F1
Barbati, ZR; Dieterich, DT; El Sayed, A; Fierer, DS; Foster, AL; Morey, T; Turner, SS1
Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J1
Li, CX; Li, W; Li, ZQ; Liang, HX; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, JY1
Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA1
Afendy, M; Cable, R; Esteban, R; Henry, L; Hunt, S; Jacobson, I; Nader, F; Stepanova, M; Sulkowski, M; Younossi, ZM; Zeuzem, S1
Bach, TA; Zaiken, K1
Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y1
Lim, SG1
Aziz, T; Hanif, FM; Laeeq, SM; Luck, NH; Mandhwani, RK; Mehdi, SH1
Bui, E; di Biase, L; Fasano, A; Freitas, ME; Picillo, M1
Castedal, M; Cederberg, S; Segenmark, M; Skoglund, C; Weiland, O1
Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y1
Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B1
Alric, L; Bellier, B; Cacoub, P; Comarmond, C; Costopoulos, M; Desbois, AC; Fontaine, H; Garrido, M; Klatzmann, D; Le Garff-Tavernier, M; Maciejewski, A; Musset, L; Pol, S; Poynard, T; Rosenzwajg, M; Saadoun, D; Si Ahmed, SN1
Bergin, C; Cannon, M; Courtney, G; Crosbie, O; De Gascun, CF; Fanning, LJ; Feeney, E; Gray, E; Houlihan, DD; Kelleher, B; Lambert, JS; Lee, J; Mallon, P; McConkey, S; McCormick, A; McKiernan, S; McNally, C; Murray, F; Norris, S; O'Leary, A; Sheehan, G; Stewart, S; Walsh, C1
Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S1
Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y1
Everson, GT; Kiser, JJ; Langness, JA; Nguyen, M; Wieland, A1
Brainard, DM; Chung, R; Fierer, DS; Hollabaugh, K; Hughes, M; Kim, A; Kiser, JJ; Macbrayne, C; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Symonds, B1
Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D1
Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R1
Chowdhury, R; Tsen, A1
Bansal, A; Dutta, U; Goyal, O; Grover, R; Kishore, H; Malhi, NS; Nanda, V; Saluja, H; Sehgal, A; Sidhu, JS; Sidhu, S; Sidhu, SS; Singh, G; Singh, R1
El Sayed, MH; Giaquinto, C; Gonzalez-Peralta, RP; Indolfi, G; Thorne, C1
Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ1
Bider-Canfield, Z; Cheetham, TC; Gharibian, D; Latt, NL; Louie, V; Mittal, R; Sahota, A; Yanny, BT1
Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A1
Angarano, G; Bruno, G; Milella, M; Saracino, A1
Barocas, JA; Beiser, M; Gaeta, JM; León, C; Linas, BP; O'Connell, JJ1
Brown, RS; Charlton, M; Curry, MP; Hunt, S; O'Leary, JG; Stepanova, M; Younossi, ZM1
Abd-Elsalam, S; Ahmed, OA; Hassan A Fouad, M; Hawash, N; Kaisar, HH; Rizk, F; Samir, H; Shabana, SST1
Alavian, SM; Behnava, B; Dolatimehr, F; Gholami-Fesharaki, M; Karimi-Sari, H; Rezaee-Zavareh, MS; Sharafi, H1
Akriviadis, E; Arvaniti, P; Bellou, A; Dalekos, GN; Goulis, I; Karatapanis, S; Kattamis, A; Koskinas, J; Kountouras, D; Kourakli, A; Maragkos, K; Papatheodoridis, GV; Petropoulou, F; Sinakos, E; Tampaki, M; Toli, B; Triantos, C; Tsiaoussis, G; Vassiliadis, T; Vlachaki, E; Zachou, K1
Arai, M; Chiba, T; Haga, Y; Imazeki, F; Kanda, T; Kato, N; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Sasaki, R; Suzuki, E; Takahashi, K; Tawada, A; Wu, S; Yasui, S; Yokosuka, O1
Haba, S; Kobayashi, Y; Matsuda, S; Miyagishima, T; Morikawa, K; Nakano, S; Oda, H; Sakamoto, N; Sarashina, K; Sogabe, S; Takahashi, K; Takahashi, T; Terashita, K; Yamamura, T; Yoshikawa, A1
Chan, HL; Lo, AO; Wong, GL; Wong, VW1
El Raziky, M; Elakel, W; Eletreby, R; Esmat, G1
Everson, GT; Jackson, WE1
Ali, A; Idrees, M; Rafique, S; Saleem, K; Wahid, B1
Akhavan, S; Calin, R; Demeret, S; Jaspard, M; Katlama, C; Mallet, V; Peytavin, G; Pourcher, V; Poynard, T; Roque-Afonso, AM; Thibault, V; Todesco, E1
Brainard, DM; Davis, MN; Dvory-Sobol, H; Etzkorn, K; Gane, EJ; Hinestrosa, F; Huang, KC; McHutchison, JG; McNally, J; Morelli, G; Osinusi, A; Shiffman, ML; Stedman, CAM; Sulkowski, MS; Thompson, AJ1
Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A1
Angiola, A; Caruso, A; Casari, S; Castelli, F; Festa, E; Gargiulo, F; Lanza, P; Nasta, P; Odolini, S; Rodella, A; Urbinati, L; Vavassori, A; Viganò, M; Zaltron, S1
Bailey, R; Borgia, S; Brainard, DM; Cooper, C; Elkhashab, M; Feld, JJ; Greenbloom, S; Huang, KC; Huchet, E; Hyland, RH; Marotta, P; Massetto, B; McHutchison, JG; Ramji, A; Shafran, SD; Svarovskaia, ES; Swain, MG; Tam, E; Vachon, ML; Willems, B; Yoshida, EM; Yun, C1
Arnon, R; Balistreri, WF; Brainard, DM; Gonzalez-Peralta, RP; Hardikar, W; Jonas, MM; Kanwar, B; Kersey, K; Kirby, B; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, KB; Shao, J; Svarovskaia, E; Wirth, S1
Alfieri, R; Andreoni, M; Angelico, M; Antonucci, FP; Babudieri, S; Bernardini, S; Biliotti, E; Bolis, M; Calvaruso, V; Casalino, P; Ceccherini-Silberstein, F; Cento, V; Cerrone, M; Craxì, A; D'Arminio Monforte, A; Danieli, E; Di Biagio, A; Di Carlo, D; Di Maio, VC; Di Paolo, D; Gianserra, L; Guedj, J; Lenci, I; Magni, CF; Melis, M; Menzaghi, B; Micheli, V; Nguyen, THT; Nicolini, LA; Parruti, G; Pasquazzi, C; Perno, CF; Polilli, E; Puoti, M; Quirino, T; Rizzardini, G; Romagnoli, D; Sarmati, L; Siciliano, M; Taliani, G; Teti, E1
Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M1
Fujikawa, T; Iwabuchi, S; Matsui, K; Nagata, M; Nakano, M; Nakazaki, H; Shimizu, H; Takatsuka, K; Tanemura, H; Watanabe, T1
Peterson, D; Van Ermen, A1
Furusyo, N; Hayashi, T; Murata, M; Ogawa, E; Toyoda, K; Ura, K1
Burman, B; Edwards, AM; Kozarek, RA; Lee, H; Shin, HP; Siddique, A; Wang, C; Zehr, T; Zeigler, A1
Angarano, G; Bruno, G; Dell'Acqua, R; Fabrizio, C; Lo Caputo, S; Milano, E; Milella, M; Monno, L; Saracino, A; Scudeller, L1
Aggarwal, R; Bhargava, R; Goel, A; Rai, P1
Caruso, V; Cenderello, G; Copetti, M; Forni, G; Gamberini, R; Ganga, R; Mangia, A; Piazzolla, V; Piga, A; Quarta, A; Santoro, R; Sarli, R1
Abdel Alem, S; Abdellatif, Z; Adel, E; Elsharkawy, A; Esmat, G; Fouad, R; Hussein, MS; Musa, S; Nagy, A; Yosry, A1
Afdhal, NH; Bacon, B; Curry, MP; Dieterich, D; Flamm, SL; Guest, L; Kowdley, KV; Lee, Y; Milligan, S; Tapper, EB; Tsai, N; Younossi, Z1
Balslev, U; Belard, E; Dalgard, O; Färkkilâ, M; Hallager, S; Heggelund, L; Karlsen, L; Krarup, H; Lagging, M; Lund Laursen, A; Madsen, LG; Noraberg, G; Skalshøi Kjær, M; Thorup Røge, B; Weiland, O; Weis, N; Øvrehus, A1
Amrose, P; Anand, S; Kumar, MS; McFall, AM; Mehta, SH; Ramasamy, B; Solomon, SS; Srikrishnan, AK; Sulkowski, MS; Thomas, DL1
Sokal, EM1
Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A1
Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P1
Abaalkhail, F; Ajlan, A; Al Sebayel, M; Al-Hamoudi, W; Al-Jedai, A; Alabbad, S; Broering, D; Elbeshbeshy, H; Elsiesy, H; Saab, S; Shawkat, M; Ullah, W; Yousif, S1
Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP1
Altice, FL; Barnard, T; Filippovych, S; Mazhnaya, A; Meteliuk, A; Zelenev, A1
Cheema, HA; Hashmi, MA1
Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D1
Barnes, E; Brown, A; de Vree, JML; Klenerman, P; Kootstra, NA; Reesink, HW; Sinnige, MJ; Stelma, F; Swadling, L; van der Ree, MH; van der Valk, M; van Nuenen, AC; Willemse, SB1
Abutidze, A; Chkhartishvili, N; Dolmazashvili, E; Karchava, M; Sharvadze, L; Tsertsvadze, T1
Kim, HJ; Lee, HW; Won, JW; Yoo, KY1
Arends, JE; Bijmolen, M; Blokzijl, H; Burger, DM; de Kanter, CTMM; de Knegt, RJ; Dofferhoff, ASM; Drenth, JPH; Lieveld, FI; Maan, R; Smolders, EJ; van der Valk, M; van Erpecum, KJ; van Tilborg, M1
Caraceni, P; Carrai, P; Donato, MF; Fagiuoli, S; Filì, D; Gianstefani, A; Martini, S; Mazzarelli, C; Melazzini, M; Montilla, S; Pani, L; Petraglia, S; Rendina, M; Russo, P; Trotta, MP; Visco-Comandini, U1
Huang, JW; Liao, HT; Tan, P; Yuan, KF1
Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX1
Bassiony, MAA; Hanafy, AS; Hussein, S; Mohamed, MS1
Abdalla, U; Abdel-Khalek, EE; Abdel-Wahab, M; Al-Refaey, AK; Al-Shobari, M; Ali, M; El-Gilany, AH; Elghawalby, AN; Elmorshedi, M; Sadani, M; Salah, T; Shiha, U; Sultan, AM; Yassen, AM1
Abd El-Wahab, EW; Nagaty, A1
Abd-Elsalam, S; Ahmad, YK; Badawi, R; Elfert, A; Sharaf-Eldin, M; Soliman, S1
Hayashi, Y; Imoto, S; Kato, A; Kim, CW; Kim, KI; Kim, SK; Kim, SR; Kobayashi, M; Kudo, M; Morimoto, E; Ohtani, A; Saijo, Y; Seo, K; Yano, Y1
Aburawash, A; Elsisi, GH; Waked, E1
Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F1
Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH1
Brown, RS; Camus, G; Copans, A; Ghali, P; Guyer, B; Haubrich, R; Kang, M; Luetkemeyer, AF; Mantry, PS; Ni, L; Rossaro, L; Satapathy, SK; Shen, X; Tam, E1
Bhardwaj, N; Brainard, D; Chang, S; Chodavarapu, K; Feld, JJ; Mangia, A; Martin, R; McNally, J; Miller, MD; Mo, H; Murrell, B; Osinusi, A; Ragonnet-Cronin, M; Sulkowski, M; Svarovskaia, ES; Wertheim, JO1
Ferenci, P; Gschwantler, M; Gutic, E; Haltmayer, H; Kozbial, K; Laferl, H; Lang, T; Luhn, J; Moser, S; Reiberger, T; Schleicher, M; Schubert, R; Schütz, A; Schwabl, P; Schwanke, C; Steindl-Munda, P1
Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA1
Andini, R; Atripaldi, L; Durante-Mangoni, E; Maiello, C; Mattucci, I; Vitrone, M; Zampino, R1
Clark, A; Dusheiko, G; Fathi, H; Hill, NR1
Kalal, C; Mohanka, R; Patel, P; Shah, S; Shukla, A; Vora, M1
Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG1
Ahmed, B; Ghaffar, A; Jalal, F; Kamran, SK; Kiran, S; Munir, B; Oranab, S; Shehzadi, S; Zahoor, MK1
AbdAllah, M; Doss, W; El Akel, W; El Kassas, M; El Shazly, H; El Shazly, Y; Elbaz, T; Elsaeed, K; Esmat, G; Gomaa, AA; Ismail, SA; Korany, M; Nasr, A; Omar, H; Said, M; Shaker, MK; Waked, I; Yousif, M1
Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U1
Carlton-Smith, C; Chung, RT; Holmes, JA; Kim, AY; Lauer, GM; Lidofsky, A; Naggie, S1
Gonzalez-Peralta, R; Henry, L; Hunt, S; Murray, K; Rosenthal, P; Schwarz, KB; Stepanova, M; Wirth, S; Younossi, ZM1
Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Kinh, N; Lai, CL; Lai, W; Lim, YS; Stepanova, M; Younossi, ZM; Yuen, MF1
Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H1
Angus, PW; George, J; Gow, P; Jeffrey, G; Mason, S; McCaughan, GW; Mitchell, J; Morales, B; Parker, FC; Roberts, SK; Strasser, SI; Tallis, C; Thompson, AJ; Thwaites, PA; Wigg, A1
Birkemose, I; Christensen, PB; Ernst, A; Holm, DK; Krarup, H; Mössner, B; Øvrehus, ALH1
Agarwal, K; Carey, I; Lampejo, T1
Fiel, MI; Putra, J; Schiano, TD1
de Avila, L; Doyle, J; Stepanova, M; Thompson, A; Younossi, I; Younossi, ZM1
Bunchorntavakul, C; Palecki, J; Reddy, KR; Tan Dat, H; Thu Thuy, PT1
Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S1
El-Amin, H; El-Khayat, H; Fouad, Y; Kamal, EM; Maher, M; Mohamed, HI; Risk, A1
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ohya, K; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y1
Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM1
Dohmen, K; Ichiki, Y; Ishibashi, H; Kawano, A; Miki, K; Morita, C; Nomura, H; Shigematsu, H; Shimoda, S; Takahashi, K; Yanagita, K1
Elfert, AA1
Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C1
Abd El Latif, Y; Alboraie, M; Doss, W; El Kassas, M; El Tahan, A; El-Serafy, M; Elakel, W; Elsaeed, K; ElShazly, Y; Esmat, G; Ezzat, S; Korany, M; Nabeel, MM; Omran, D1
Asensi-Diez, R; Del Rio-Valencia, JC; Madera-Pajin, R; Muñoz-Castillo, I; Yunquera-Romero, L1
Scott, LJ1
Brainard, DM; Cheng, J; Dou, X; Duan, Z; Gao, ZL; German, P; Gong, G; Hou, JL; Hu, P; Jia, J; Jiang, D; Jiang, J; Kersey, K; Knox, SJ; Li, J; Li, L; Li, W; Lin, F; Massetto, B; Mo, H; Mou, Z; Nan, Y; Ning, Q; Niu, JQ; Tang, H; Wang, G; Wei, L; Wu, S; Xie, Q; Xu, M; Yang, JC; Yang, Y; Zhang, LL1
Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH1
Ali, M; Aziz, H; Raza, A; Shinwari, ZK; Zia, A; Zia, M1
Bittermann, T; Weinberg, E1
Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS1
Afdhal, N; Babusis, D; Curry, MP; Kirby, B; Mathias, A; McHutchison, JG; Murakami, E; Park, Y; Ray, AS; Wang, T1
Fan, R; Hou, J; Liang, X; Sun, J1
Imnadze, T; Mikadze, I; Vashakidze, E1
Agarwal, K; Asante-Appiah, E; Barclay, S; Barr, E; Brown, AS; Collier, J; Cramp, ME; Du, J; Forton, DM; Foster, GR; Fox, R; Gilbert, CL; Gordon, F; Haber, B; Moreea, S; Mutimer, DJ; Robertson, MN; Rosenberg, WM; Ryder, SD; Ustianowski, A; Wahl, J1
Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P1
Abravanel, F; Akhavan, S; Calmus, Y; Conti, F; Guillemain, R; Lecuyer, L; Marcelin, AG; Mazzola, A; Peytavin, G; Poynard, T; Roque-Afonso, AM; Todesco, E1
Bergmann, OM; Björnsson, ES; Fridriksdottir, RH; Gottfredsson, M; Gudnason, T; Hansdottir, I; Heimisdottir, M; Hellard, M; Johannsson, B; Löve, A; Löve, TJ; Olafsson, S; Runarsdottir, V; Sigurdardottir, B; Tyrfingsson, T1
Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R1
Ansari, MA; Barnes, E; Bowden, R; Hudson, E; Klenerman, P; Marchi, E; Mclean, A; Pedergnana, V; Ramamurthy, N; Spencer, CCA1
Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, M1
Berthillon, P; Bordes, I; Chemin, I; Crouy, S; Larrat, S; Leroy, V; Maynard, M; Petit, MA; Pradat, P; Scholtès, C; Trépo, C; Virlogeux, V; Zoulim, F1
El-Raziky, M; Elsharkawy, A; Fouad, A; Khairy, M; Salama, A; Tantawy, O1
Cherian, R; Driscoll, C; Genther, K; Goode, MB; Lee, H; Lewis, S; Luketic, VA; Martin, K; Matherly, S; Patel, V; Puri, P; Sanyal, AJ; Siddiqui, MS; Smith, P; Sterling, RK; Stravitz, RT1
Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE1
Aoufi-Rabih, S; Fabrizi, F; García-Agudo, R; González-Corvillo, C; Salgueira-Lazo, M1
Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI1
Benson, AA; Lederman, N; Safadi, R; Wolf, D1
Masumoto, A; Miyazaki, M; Motomura, K; Tanaka, K; Yada, M1
Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A1
Jang, H; Jin, YJ; Kim, CW; Kim, L; Yoon, CH1
Elfiky, AA; Ismail, AM1
Adragão, T; Birne, R; Bruges, M; Carvalho, L; Chagas, C; Jorge, C; Lebre, L; Machado, D; Matias, P; Nascimento, C; Querido, S; Weigert, A1
Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML1
ElBasiony, M; Hassan, AA; Mikhail, NNH; Shiha, G; Soliman, R1
Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T1
Gupta, E; Kataria, A; Nayak, SL; Sarin, SK1
Cervino, L; Hynicka, LM1
Furqan, S; Jabeen, S; Rashid, O1
Basile, M; Cicchetti, A; Drago, C; Favaretti, C; Kheiraoui, F; Rolli, FR; Ruggeri, M1
Atsumi, T; Fujieda, Y; Nakai, M; Nakamura, H; Yasuda, S1
Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M1
Abbas, B; Asem, N; Elsharkawy, A; Esmat, G; Gomaa, A; Hassany, M; Maged, A; Mehrez, M; Mostafa, Z; Soliman, M1
Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM1
Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM1
Abdallah, F; El Tarabily, M; Ibrahim, M; Mohamed, G1
Abdel-Gabaar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI1
Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Nozawa, Y; Owaki, T; Sano, T; Sato, H; Seki, K; Yoshida, T1
Elmasry, MS; Elsayed, HM; Hassan, WS; Zidan, DW1
Zhang, DZ; Zhang, QF1
Kamiya, K; Komine, M; Maekawa, T; Murata, S; Ohtsuki, M; Waki, Y1
Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ1
Berg, CP; Berg, T; Blessin, U; Engelmann, C; Grottenthaler, JM; Harrer, E; Hinterleitner, C; Lauer, UM; Malek, NP; Pathil, A; Sarrazin, C; Scholten, S; Schott, E; Seybold, U; Spengler, U; Steurer, M; Stremmel, W; von Hahn, T; Wedemeyer, H; Welker, MW; Werner, CR1
Sadler, MD1
Abd El Latif, Y; Doss, W; El Kassas, M; El Shazly, Y; El Tahan, A; Elbadry, M; Esmat, G; Farid, AM; Fontanet, A; Funk, AL; Sherief, A; Shimakawa, Y; Vasiliu, A; Youssef, N1
Christensen, S; Sarrazin, C; Schulze Zur Wiesch, J; Vermehren, J; von Felden, J1
Höner Zu Siederdissen, C; Maasoumy, B1
Bhamidimarri, KR; Chu, D; Han, SB; Hu, KQ; Lee, TP; Ma, X; Mohanty, SR; Pan, CQ; Park, J; Tiongson, BC; Tong, M; Wang, D; Xiao, PY1
Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I1
Benfield, T; Bukh, J; Fahnøe, U; Galli, A; Mejer, N; Ramirez, S1
Biliotti, E; De Angelis, M; Esvan, R; Franchi, C; Garbuglia, AR; Palazzo, D; Spaziante, M; Taliani, G; Volpicelli, L1
Alper, CJ; Clements, K; Greenwood, BC; Hydery, T; Jeffrey, PL; Kouris, G; Lavitas, P; Lenz, K; Price, M1
Andrade, RJ; Brainard, DM; Buti, M; Calleja, JL; Camus, G; Carrión, JA; Casado, M; Esteban, R; Forns, X; Lens, S; McNabb, B; Morano Amado, LE; Morillas, RM; Pascasio Acevedo, JM; Pineda, JA; Riveiro-Barciela, M; Rivero, A; Rodríguez, M; Stamm, LM; Subramanian, GM; Turnes, J; Zhang, G1
Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Lai, CL; Lim, YS; Nguyen, KV; Stepanova, M; Wei, L; Younossi, ZM1
Barone, CR; Bonamigo, RR; Boza, JC; Oliveira, FB; Pires, GC; Rossi, SD; Silva, M1
Aghemo, A; Brancaccio, G; D'Offizi, G; Gaeta, GB; Giorgini, A; Hasson, H; Menzaghi, B; Palma, M; Termini, R1
Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N1
Abdel Wahed, WY; Ahmed, EI; Ahmed, TI; Hassan, EA1
Al-Deen Abead, M; Baraka, MA; Gomaa, AA; Hussein, AK; Wahsh, EA1
Boeker, KHW; Buggisch, P; Günther, R; Hüppe, D; Maasoumy, B; Manns, MP; Mauss, S; Müller, T; Sarrazin, C; Vermehren, J; Wedemeyer, H; Zimmermann, T1
Brainard, DM; Camus, G; Chayama, K; De-Oertel, S; Enomoto, H; Ide, T; Ikeda, F; Izumi, N; Jiang, D; Kakizaki, S; Kawakami, Y; Kurosaki, M; McHutchison, JG; McNabb, BL; Mizokami, M; Mochida, S; Stamm, LM; Takaguchi, K; Takehara, T; Tanaka, Y; Toyoda, H; Ueno, Y; Yatsuhashi, H1
Brieva, T; Frias, M; Rivero, A; Rivero-Juarez, A1
Bacca, D; Cenderello, G; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Mazzola, M; Minerva, N; Palmieri, V; Piazzola, V; Potenza, D; Santoro, R; Sogari, F; Terreni, N1
Arnon, R; Balistreri, WF; Bansal, S; Brainard, DM; Evans, HM; Garrison, KL; Gillis, LA; Gonzalez-Peralta, RP; Jonas, MM; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Narkewicz, MR; Parhy, B; Rosenthal, P; Schwarz, K; Shao, J; Wen, J; Whitworth, S1
Abdel-Ghafar, TS; Abdelkareem, M; Abdelsameea, E; Abozeid, M; Alsebaey, A; Elfayomy, M; Elhelbawy, M; Fekry, M; Othman, W; Rewisha, E; Rgab, A; Sabry, A; Shebl, N; Waked, I1
Chakraborty, S; Garlapati, P; Gayam, V; Gill, A; Guss, D; Khalid, M; Mandal, AK; Mansour, M; Mohanty, S; Mukhtar, O; Sherigar, J; Shrestha, B; Tiongson, B1
Abdellatif, Z; Anwar, I; Bekheet, N; El-Nahaas, SM; Elhossary, W; Elsharkawy, A; Esmat, G; Fouad, R; Khairy, M; Maher, RM1
Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S1
Cabello, V; Juampérez, J; Julio, E; Mercadal-Hally, M; Quintero, J; Rodrigo, C; Segarra, Ó; Soler-Palacín, P1
Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM1
Abid, S; Abraham, P; Abu Bakar, N; Ahmed, T; Arisar, FAQ; Bwa, AH; Chen, KP; Dan, YY; Dhore, P; Eapen, CE; Goh, KL; Hamid, S; Hj Md Said, RB; Ho, SH; Jafri, W; Kamat, M; Koshy, A; Lee, YM; Lim, SG; Madan, K; Mehta, R; Mohamed, R; Phyo, WW; Piratvisuth, T; Shah, SR; Shukla, A; Tan, SS; Tanwandee, T; Tee, HP; Tyagi, S; Wadhawan, M; Win, KM; Yang, WL; Yin, TP1
Bischoff, J; Rockstroh, JK1
Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N1
Yeon, JE1
Jacobson, IM1
Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G1
Abd-Elsalam, S; Badawi, R; Elfert, A; Elkhouly, RA; Elnawasany, S; Hawash, N; Kobtan, A; Mansour, L; Selim, A; Soliman, S; Yousef, M1
Chang, CH; Chen, DS; Chen, PJ; Hong, CM; Huang, YJ; Hung, CC; Kao, JH; Liu, CH; Liu, CJ; Liu, WC; Su, TH; Sun, HY; Tseng, TC; Yang, HC; Yang, SS1
Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Satsangi, S; Taneja, S1
Chen, DZ; Chen, KD; Li, LJ; Ou, HL; Su, JW; Wu, XX; Xu, XW; Yao, HP; Yu, HY1
Buonanno, P; Camera, S; Caporaso, N; Capuano, I; Donnarumma, L; Ferreri, L; Morisco, F; Sabbatini, M1
Abdelsameea, E; Essa, M; Sabry, A; Salama, M; Tharwa, ES1
Chen, EQ; Deng, R; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wang, YH; Yuan, M1
Almeida, J; Arrelaro, R; Cintra, M; Corrêa, B; Cunha-Silva, M; Lopes, T; Lorena, S; Mazo, D; Rabello, M; Sevá-Pereira, T; Torino, AB; Vaz, N1
Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC1
Fukaya, Y; Hirosawa, T; Imai, M; Isoda, N; Kurata, H; Miura, K; Morimoto, N; Murayama, K; Murohisa, T; Nomoto, H; Numao, N; Okamura, Y; Ozawa, I; Sato, T; Tahara, T; Takaoka, Y; Tano, S; Tsukui, M; Watanabe, S; Yamamoto, H; Yoshizumi, H1
Cicchetti, A; De Solda, F; Drago, C; Kondili, LA; Nappi, C; Rolli, FR; Ruggeri, M1
Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB1
Ghesquiere, W; Huhn, GD; Linaberry, M; McPhee, F; Noviello, S; Poordad, F; Ramji, A; Shafran, SD; Shiffman, ML; Wong, A; Wong, F; Yang, R1
Ali, Q; Imran, M; Iqbal, K; Jamal, A; Kalam, I; Ullah, S; Waqar, AB1
Aartun, J; Kottilil, S; Masur, H; Meissner, EG; Orr, C1
Avril, E; Bouscaillou, J; Butsashvili, M; Etienne, A; Gamezardashvili, A; Inaridze, I; Kamkamidze, G; Kharshiladze, D; Kikvidze, T; Labartkava, K; Le Pluart, D; Luhmann, N1
De Maria, C; Ghidotti, I; Giannini, EG; Grillo, F1
Khaliq, S; Raza, SM1
Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA1
Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC1
Choi, HY; Chung, W; Jang, ES; Jeong, SH; Ki, M; Kim, KA1
Cenderello, G; Di Biagio, A; Taramasso, L1
Back, DJ; Burger, DM; Colbers, A; de Knegt, RJ; Drenth, JPH; El-Sherif, O; Honkoop, P; Smolders, EJ; van Seyen, M; van Wijngaarden, P; Wouthuyzen-Bakker, M1
Zeuzem, S1
Fattehi, MR; Ghorbani, M; Hojati, SA; Maserat, E; Safarpour, A1
Aguilar, H; Asatryan, A; Asselah, T; Baumgarten, A; Conway, B; Dore, GJ; Foster, GR; Grebely, J; Gschwantler, M; Hu, Y; Jackson, D; Mensa, FJ; Sherman, KE; Tomasiewicz, K; Wang, S1
Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH1
Drinane, M; Jing Wang, X; Watt, K1
Aboufarrag, GA; Lashen, SA; Madkour, MA; Shamseya, MM1
Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC2
Kimura, K1
Abou El-Khier, NT; Abousamra, NK; Arafa, MM; Eladl, E; Elhammady, D; Esmael, ME; Shahin, D; Shaker, G; Sharaf-Eldeen, O1
Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SHH; Sulaiman, AS; Zulkifly, S1
Elgouhary, SM; Mowafy, MA; Said-Ahmed, KE1
Abushouk, AI; Al-Husseini, M; El-Raey, F; Johar, D; Mohammed, EG; Montasser, MF; Salaheldin, M; Zaky, S1
Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E1
Dohi, T; Jain, A; Kadry, Z; Krok, KL; Miller, D; Riley, TR; Schreibman, I; Sharma, R1
Barker, L; Jiles, RB; White, JZ; Yin, S1
El-Hamamsy, M; El-Meteini, M; Mansy, AE; Montasser, IF; Nabet, DE1
Kamar, N; Pan, Q1
Drinane, M1
Akarca, US; Akdogan, M; Akhan, S; Aladag, M; Ataseven, H; Cakaloglu, Y; Cavus, B; Demir, M; Erol, C; Ersoz, G; Gunduz, F; Gunsar, F; Idilman, R; Iliaz, R; Karasu, Z; Kaymakoglu, S; Kiyici, M; Koklu, H; Koksal, AS; Koksal, İ; Ozgenel, M; Sahin, M; Tabak, F; Turan, İ1
Basha, MAA; Bassiony, MA; Hanafy, AS1
Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I1
Aziz, T; Hanif, FM; Lail, G; Luck, NH; Mandhwani, R1
Brandão, ABM; Cantisani, GPC; Costabeber, AM; Fleck Junior, AM; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Meine, MH; Mucenic, M; Rossato, G; Sacco, FKR; Schlindwein, ES; Zanotelli, ML1
Akahane, T; Furukawa, M; Kaji, K; Kawaratani, H; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Okura, Y; Saikawa, S; Sato, S; Sawada, Y; Seki, K; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H1
Farias, MR; Foppa, AA; Gomes, LO; Rosa, JAD; Rover, MRM; Teixeira, MR1
Brainard, DM; Gao, Z; Huang, R; Jiang, D; Li, W; Massetto, B; Mo, H; Rao, H; Stamm, LM; Wei, L; Xie, Q1
Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q1
Cho, M; Han, SY; Heo, J; Kim, DU; Kim, GH; Kim, HH; Park, SG; Park, YJ; Pyeon, SI; Song, GA; Woo, HY1
Baker, MM; Belal, TS; Hammad, SF1
Atanasov, PK; Buggisch, P; Lee, J; Petersen, J; Stoehr, A; Supiot, R; Ting, J; Wursthorn, K1
Aldir, I; Bana E Costa, T; Carvalho, A; Chagas, C; Correia, JM; Falcão, F; Farinha, H; Lebre, L; Lopes, C; Mansinho, K; Marques, S; Miranda, AC; Mirco, A; Peixe, P; Perez, R; Viegas, E1
Afify, S; Alboraie, M; Algaber, MA; Doss, W; El Halwagy, H; El Kassas, M; El Latif, YA; El Tahan, A; Elsaeed, K; Elserafy, M; Omar, H1
Chen, M; Hu, P; Liu, K; Pan, Z; Peng, M; Qiu, K; Ren, H; Shen, Y; Xue, W1
Birerdinc, A; Curry, MP; de Avila, L; Escheik, C; Estep, JM; Gerber, L; Golabi, P; Stepanova, M; Weinstein, AA; Younossi, ZM1
Babudieri, S; Barbarini, G; Candilo, FD; Cariti, G; Dell'Isola, S; Distefano, M; Ettorre, GM; Fontanella, L; Giannelli, V; Iovinella, V; Ippolito, AM; Izzi, A; Marignani, M; Messina, V; Moretti, A; Palitti, VP; Pellicelli, A; Pompili, M; Scifo, G; Tarquini, P; Vennarecci, G; Vignally, P1
Cenderello, G; Ciancio, A; Copetti, M; Lorusso, C; Mangia, A; Minisini, R; Orlandini, A; Piazzolla, V; Santoro, R; Squillante, MM; Verucchi, G1
Cascio, A; Cervo, A; Colomba, C; Di Carlo, P; Firenze, A; Saporito, L; Tolomeo, M; Trizzino, M1
Bock, CT; Eurich, D; Gerlach, UA; Hofmann, J; Maurer, MM; Mueller, T; Papp, CP; Schulz, M1
Pawlotsky, JM1
El-Kosasy, AM; Hussein, LA; Magdy, N; Youssef, AA1
Choi, JW; Ko, SY; Seo, HY; Seo, MS; Yoon, SY1
Bwa, AH; Hlaing, NKT; Kyaw, AMM; Lin, S; Loza, BL; Maung, MZ; Maung, ST; Myint, KT; Nangia, G; Reddy, KR; Sein Win, S; Tun, KT; Win, KM1
Chtioui, H; Fraga, M; Gouttenoire, J; Marcu, C; Moradpour, D; Pascual, M; Sahli, R; Vionnet, J1
Bermúdez, C; Cheinquer, H; Coelho Borges, S; de Araujo, A; de Maman, Í; Fleck, A; Gadano, A; Garrastazul, P; Haddad, L; Kliemann, D; Marciano, S; Mendizabal, M; Nader, LA; Piñero, F; Ridruejo, E; Silva, M; Wolff, FH1
Deng, H; Fan, X; Han, Q; Li, N; Liu, Z; Wang, X; Wang, Y; Zhang, K; Zhang, X1
Angelico, M; Antonucci, F; Armenia, D; Bellocchi, MC; Carioti, L; Ceccherini-Silberstein, F; Cento, V; Ciancio Manuelli, M; De Leonardis, F; Lenci, I; Manzia, TM; Milana, M; Perno, CF; Sforza, D; Sorbo, MC; Tisone, G1
Abdelrazik, M; Aboushady, M; Alwassief, A; Elbahrawy, A; Elmestikawy, A; Shahba, H; Ziada, D1
Amiot, X; Arotcarena, R; Cadranel, JF; Causse, X; Garioud, A; Halfon, P; Heng, R; Lucidarme, D; Medmoun, M; Mokhtari, C; Ollivier-Hourmand, I; Pariente, A; Pulwermacher, P; Rémy, AJ; Renou, C; Rosa-Hézode, I; Zanditenas, D; Zougmoré, H1
Brainard, DM; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; Luetkemeyer, A; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Rwema, S; Vu, V1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Igarashi, A; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K1
Balistreri, WF; Bansal, S; Brainard, DM; Davison, S; Feiterna-Sperling, C; Gillis, LA; Gonzalez-Peralta, RP; Hsueh, CH; Indolfi, G; Jonas, MM; Kelly, DA; Lin, CH; Massetto, B; Murray, KF; Nightingale, S; Parhy, B; Rosenthal, P; Schwarz, KB; Shao, J; Sokal, EM; Wirth, S1
Wahid, B2
Kanda, T; Kaneko, T; Komoriya, T; Kuroda, K; Matsumoto, N; Matsuoka, S; Moriyama, M; Nakajima, N; Nirei, K; Ogawa, M; Shibata, T; Takayama, T; Tamura, A; Yamamoto, T; Yamazaki, M1
Chu, CJ; Hou, MC; Huang, YH; Wu, SH1
Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ1
Amory, C; Gardenier, D; Weiss, JJ; Woody, A1
Arora, S; Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Roy, A; Satsangi, S; Taneja, S1
A, M; Abd-Elsamie, E; Badawy, ER; ElMelegy, TT; Hassaballa, AE; Kamal-ElDin, TM; Mekky, MA; Zahran, AM1
Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F1
Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A1
Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lee, SD; Lin, CC; Su, CW; Wang, YJ; Wu, SH1
Gao, XH; Jing, P1
Gaballah, AH; Ghazy, AA; Mostafa, H; Osman, EM; Rashwan, EA; Tawfik, S1
Afendy, A; Gaggar, A; Jacobson, IM; Lalezari, J; Lawitz, EJ; Muir, AJ; Myers, RP; Nader, F; Racila, A; Reddy, KR; Ruane, PJ; Schwabe, C; Stepanova, M; Younossi, I; Younossi, ZM1
Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM1
Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP1
Fried, MW; Hassan, MA; Hinestrosa, F; Jacobson, IM; Kort, JJ; Larsen, L; Lok, AS; Lu, W; Michael, LC; Morelli, G; Nelson, DR; Pearlman, BL; Peter, JA; Reddy, KR; Shiffman, ML; Sulkowski, MS; Vainorius, M; Wang, GP; Willner, I1
Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ1
Merat, S1
Grasso, AG; Loiacono, S; Maestro, A; Maximova, N; Sonzogni, A; Zanon, D1
Aguiar, BF; Bittar, C; Campos, GRF; Marques, NN; Martinelli, ALC; Molina, BF; Pereira, LRL; Rahal, P; Rodrigues, JPV; Souza, FF1
Darwish, NHE; Elbasiony, M; Mousa, SA; Shiha, G; Soliman, R2
Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T1
Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S1
Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V1
Alvarez, M; Bartlett, S; Binka, M; Butt, ZA; Chong, M; Cook, D; Darvishian, M; Janjua, NZ; Krajden, M; Pearce, ME; Ramji, A; Rossi, C; Samji, H; Tyndall, M; Wong, J; Wong, S; Yoshida, EM; Yu, A1
Aimono, Y; Kamoshida, T; Kogo, M; Kohyama, N; Yamamoto, T1
Attia, D; Doss, W; Ebeid, B; El Raziky, M; El Serafy, M; El-Khayat, H; Esmat, G; Fouad, Y; Gomaa, A; Hasseb, A; Kamal, EM; Mahmoud, H; Sameh, Y1
Calil-Elias, S; Crisante, VC; Cursino, CN; de Almeida, RMVR; Duarte, GDS; Giordani, F; Monteiro, PGO; Vieira, TBQ; Xavier, AR1
Abd El-Wahab, EW; Helmy, SH; Nagaty, A1
Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C1
Abdelkawy, KS; Ebaid, NF; El-Haggar, SM; El-Magd, MA; Elbarbry, FA; Ziada, DH1
Chaikledkaew, U; Due, OT; Genuino, AJM; Sobhonslidsuk, A; Thakkinstian, A1
Abdel Haleem, H; Abdel-Razek, W; Anees, M; El-Sayed, MH; El-Serafy, M; El-Shazly, Y; Eletreby, R; Elkhouly, R; Elshenawy, M; Esmat, G; Hamdy, M; Hassany, M; Kamal, E; Kasem, G; Salama, M; Salama, R; Shafeek, A1
Costa, J; Forns, X; García-López, M; Lens, S; Navasa, M; Pérez-Del-Pulgar, S; Sastre, L1
Abutidze, A; Averhoff, F; Butsashvili, M; Chkhartishvili, N; Ezugbaia, M; Gamkrelidze, A; Gvinjilia, L; Kerashvili, V; Kvaratskhelia, V; Metreveli, D; Morgan, J; Nasrullah, M; Shadaker, S; Sharvadze, L; Tsertsvadze, T1
Abdel Alem, S; Abdel Aziz, H; Abdellatif, Z; Al Askalany, M; Cordie, A; El Akel, W; Elsharkawy, A; Esmat, G; Kamal, W; Kamel, S; Kandeel, A; Meshaal, S1
Boccuto, A; Dragoni, F; Giammarino, F; Giannini, A; Mastrangelo, E; Mori, M; Picarazzi, F; Saladini, F; Vicenti, I; Zazzi, M1
Cui, LY; Liu, LD; Nan, YM; Zhao, W1
Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C1
Aghemo, A; Aimo, G; Baiguera, C; Bella, D; Bernasconi, DP; Bhoori, S; Boldizzoni, R; Bonfanti, P; Capretti, A; Carderi, I; Carriero, C; Centenaro, R; Ciaccio, A; Colella, E; Cologni, G; Colombo, A; Colombo, S; D'Ambrosio, R; d'Arminio Monforte, A; De Bona, A; Degasperi, E; Del Poggio, P; Di Marco, M; Dionigi, E; Fagiuoli, S; Fava, M; Gatti, F; Giglio, O; Giorgini, A; Graffeo, M; Grossi, PA; Hasson, H; Lampertico, P; Landonio, S; Lapadula, G; Lazzaroni, S; Liani, C; Lombardi, A; Menzaghi, B; Migliorino, GM; Molteni, C; Noventa, F; Pagnucco, L; Pan, A; Pasulo, L; Perini, P; Pigozzi, MG; Polo, S; Puoti, M; Rizzardini, G; Rossotti, R; Rumi, MG; Schiavini, M; Soria, A; Spinelli, O; Spinetti, A; Terreni, N; Uberti-Foppa, C; Valenti, L; Valsecchi, MG; Viganò, M; Viganò, P; Vinci, M1
Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ1
Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE1
Abbasy, M; Abdu Allah, AM; Elimam, H; Elnaidany, N; Essa, A; Mohamed Ibraheem, KI; Nada, A; Sabry, A; Shehab-Eldeen, S1
Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG1
Sirinawasatien, A; Techasirioangkun, T1
Elfiky, AA1
Bunchorntavakul, C; Charatcharoenwitthaya, P; Chonprasertsuk, S; Komolmit, P; Piratvisuth, T; Sanpajit, T; Sethasine, S; Siripipattanamongkol, C; Sobhonslidsuk, A; Sukeepaisarnjaroen, W; Sutthivana, C; Tangkijvanich, P; Tanwandee, T; Wongpaitoon, V1
Aghayeva, S; Asiller, ÖÖ; Balkan, A; Çalışkan Kartal, A; Demir, M; Erarslan, E; Gülşen, MT; Güner, R; Köksal, I; Örmeci, N; Sezgin, O; Yaraş, S1
Abou-Samra, AB; Butt, AA; Nasir, B; Rasool, S; Rubi, G; Tayyab, GUN1
El-Sayed, HM; Elmasry, MS; Hassan, WS; Shalaby, A; Zidan, DW1
Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P1
Che, D; Lu, Y; Wu, B; Zhou, H1
Abd-Elsalam, SM; Abdulaziz, BA; El Attar, IH; El Kassas, M; Emadeldeen, M; Said, EM1
Balkan, S; Brucker, C; Chhit, D; Dousset, JP; Hang, V; Iwamoto, M; Jolivet, P; Kien, A; Le Paih, M; Ly, S; Marquardt, T; O'Keefe, D; Sann, K; Zhang, M1
Khalil, H; Kim, NG; Kullar, R; Saab, S1
Bernhard, B; Stickel, F1
Barnes, E; Chau, NVV; Cooke, GS; McCabe, L; Pett, SL; Walker, AS; White, IR1
Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M1
Day, J; Le, HM; Le, PT; Nghiem, NM; Nguyen, DT; Rahman, M; Tran, TTT; Vo, QM1
Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C1
Borgia, SM; Brown, RS; Carrat, F; Doucette, K; Fagiuoli, S; Khalili, M; Lampertico, P; Losappio, R; Mangia, A; Mertens, M; Milligan, S; Ntalla, I; Ouzan, D; Papatheodoridis, G; Pérez-Hernandez, F; Ramji, A; Ramroth, H; Shafran, SD; Turnes, J; Vanstraelen, K; Wedemeyer, H; Wick, N1
Barbera, F; Conaldi, PG; Curcio, G; Gallo, A; Pietrosi, G; Russelli, G; Tuzzolino, F; Vizzini, G; Volpes, R1
Altıntaş, E; Ateş, F; Özdoğan, O; Sezgin, O; Üçbilek, E; Yaraş, S1
Bruchfeld, A1
Bonacini, M; Brainard, DM; De-Oertel, S; Flamm, SL; Gane, EJ; Gordon, SC; Huang, J; Hyland, RH; Kirby, BJ; Landis, CS; Lawitz, E; Maliakkal, BJ; Ortiz-Lasanta, G; Osinusi, AO; Robson, R; Zhang, J1
Batista, AD; da Silva Sacerdote, AB; de Barros Barreto, S; Filgueira, NA; Lopes, EP1
Alhusseini, MM; Mohamed, GA; Salama, MM; Saleh, SA1
Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH1
Ahmed, H; Elsadek, HM; Elsayed, IA; Gendia, MA; Gouda, TM; Lbrahim, NF; Magdy, MM; Sadek, AMEM; Shafeik, H; Shendi, AM; Yousif, MM; Zahran, MH; Zaki, AM1
Applegate, TL; Barash, D; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Martinello, M; Matthews, GV; Uprichard, SL; Walsh, K; Yardeni, D1
Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lai, WT; Lee, HC; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML1
Aikata, H; Chayama, K; Fukuhara, T; Hayes, CN; Imamura, M; Mori, N; Ohya, K; Takaki, S; Tsuji, K; Yamaguchi, S1
Attia, A; Baudoin, M; Boyer, S; Kouanfack, C; Lacombe, K; Lemoine, M; Moh, R; Nishimwe, ML; Rouveau, N; Seydi, M; Sylla, B; Woode, ME1
Abdel Alem, S; Abdellatif, Z; Abdo, M; Moustafa, A; Rabiee, A1
Abbaspour Kasgari, H; Alikhani, A; Babamahmoodi, F; Davoudi Badabi, AR; Davoudi, L; Garratt, A; Hedayatizadeh Omran, A; Hill, A; Levi, J; Merat, S; Moradi, S; Saeedi, M; Shabani, AM; Simmons, B; Tirgar Fakheri, H; Wentzel, H1
Bitaraf, S; Eslami, G; Esmaeilian, H; Freeman, J; Hajizadeh Farsani, M; Hill, A; Jafari Kashi, AH; Jelvay, S; Lotfi, Z; Marjani, S; Mobarak, M; Mobarak, S; Momtazan, M; Mousaviasl, S; Radmanesh, E; Sadeghi, A; Salmanzadeh, S; Simmons, B; Tabibi, R; Talebzadeh, SM; Wentzel, H; Wickramatillake, A1
Cázares-Cortazar, A; Chapararro-Sánchez, A; de la Luz Martínez-Rodríguez, M; Gaytán-Martínez, J; Mata-Marín, JA; Mauss, S; Ocaña-Mondragón, A; Uribe-Noguez, LA; Villavicencio-Ferrel, PE1
Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH1
Baicus, C; Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iacob, S; Iliescu, L; Istratescu, D; Manuc, M; Meianu, C; Pop, CS; Preda, C; Stanciu, C; Tieranu, C; Trifan, A; Tugui, L; Voiosu, T1
Anees, M; Doss, W; El Akel, W; Eletreby, R; Esmat, G; Hashem, A; Hassany, M; Helmy, A; Khalaf, N; Kobtan, A; Mansour, S; Naguib, M1
Gandjour, A1
Masuda, T; Miyasaka, A; Okamoto, H; Suzuki, A; Takikawa, Y; Yoshida, Y1
Barrett, BK; Chan, J; Feld, JJ; Hamadeh, A; Kim, JJ; Wong, WWL1
Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L1
Abd El-Maksoud, MDE; Ahmed, AE; Ahmed, OM; El-Garem, H; Gamal, A; Sakr, AA1
Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML1
Al-Tawashi, AS; Alaa, AM; Awwad, MA; El-Derany, MO; Eltobgy, MM; Gharib, MM; Kasem, MH; Mostafa, AM; Moubarak, AS; Omar, HM; Saafan, HA1
Chen, YM; Mei, YY; Wu, YK; Xu, WX; Zhang, XH1
Abdelbaser, ES; Elsadek, HM; Emara, MH; Farag, AA; Soliman, HH1
Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ1
Farooq, MO; Malik, K; Mengal, FUA; Salim, A1
Choi, IS; Kim, KM; Shim, SG1
Ali, M; Ali, S; Haque, S; Lougher, E; Nawaz, MS; Paudyal, V; Rasheed, F; Ur-Rehman, T1
Kottilil, S; Masur, H; Meissner, EG; Orr, C; Xu, W1
Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iliescu, L; Istratescu, D; Manuc, M; Pop, CS; Preda, CM; Tieranu, C; Voiosu, T1
Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, JJ; Huang, KJ; Huang, YJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Yang, SS1
Abdallah, OE; Abdel Hammed, OM; Elharrif, MG; Elwan, AW; Mahfouz, MK; Maksoud H A, A; Ragab AboZaid, OA1
Bourliere, M; Buti, M; Chokkalingam, A; Colombo, M; Esteban, R; Gaggar, A; Henry, L; Mangia, A; Manns, M; Muir, A; Nader, F; Papatheodoridis, GV; Racila, A; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S1
Cole, JL; Stark, JE1
Han, QY; He, S; Liu, ZW; Wang, XY1
Adenugba, A; Geissler, EK; Hornung, M; Junger, H; Kupke, P; Lang, H; Marquardt, JU; Peschel, G; Schlitt, HJ; Weigand, K; Werner, JM; Zimmermann, T1
Chan, C; Kulik, L; Martin, MT; Patel, S1
Fedorchenko, SV; Klimenko, Z; Martynovych, T; Solianyk, I1
Sarrazin, C1
Chuma, M; Fukuda, H; Hara, K; Kondo, M; Maeda, S; Morimoto, M; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Tanaka, K; Yamanaka, T1
El-Sayed, EM; Hassanien, KS; Helal, GK; Ismail, RS; Zakarya, ZM1
Dietz, J; Sarrazin, C1
Aldunate, F; Chiodi, D; Cristina, J; Echeverría, N; Hernández, N; López, P; Moratorio, G; Moreno, P; Sánchez-Cicerón, A; Soñora, M1
AbdAllah, M; Abdel-Razek, W; Alalfy, M; Alboraie, M; Ammar, I; Doss, W; El Akel, W; El-Bendary, M; El-Sayed, MH; El-Serafy, M; Elbaz, T; Esmat, G; Gomaa, A; Hassany, M; Hefny, Z; Kamal, E; Okasha, A; Shaaban, E1
Dehghan Manshadi, SA; Kalantari, S; Karimi, J; Malekzadeh, R; Malekzadeh, Z; Mardani, M; Merat, D; Merat, S; Mirminachi, B; Mohraz, M; Nikbin, M; Norouzi, A; Poustchi, H; Rasoolinejad, M; Sali, S; Sedghi, R; Sharifi, AH; Somi, MH; Tabarsi, P; Tayeri, K1
Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U1
Amano, N; Genda, T; Ikeda, Y; Kabemura, D; Kita, Y; Murata, A; Sato, S; Shimada, Y; Tsuzura, H; Yatagai, N1
Bourlière, M; Meszaros, M; Ouzan, D; Pageaux, GP; Tran, A; Truchi, R1
Miyasaka, A; Suzuki, A; Takikawa, Y; Yoshida, Y1
Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S1
Bai, L; Chen, L; Du, L; He, M; Kang, S; Li, C; Ma, F; Tang, H1
Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT1
Barbaliscia, S; Bruzzone, B; Cassol, C; Caudai, C; Ceccherini-Silberstein, F; Coppola, N; Cuomo, N; Di Maio, VC; Micheli, V; Monno, L; Montagnani, F; On Behalf Of The Hcv Virology Italian Resistance Network Vironet, C; Paglicci, L; Paolucci, S; Rossetti, B; Santantonio, T; Zanelli, G; Zazzi, M1
Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y1
Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C1
Darling, JM; Di Bisceglie, A; Dong, M; Evon, DM; Fishbein, DA; Fried, MW; Hinestrosa, F; Horne, PM; Khalili, M; Kixmiller, S; Lok, AS; Michael, L; Moon, JS; Morelli, G; Muir, AJ; Nelson, DR; Pearlman, B; Peter, J; Rajender Reddy, K; Segal, JB; Sherman, KE; Shiffman, ML; Sloan, A; Stewart, PW; Sulkowski, MS; Vainorius, M; Wadsworth, S1
Chang, CC; Chang, CH; Chang, CY; Chen, CY; Chen, JJ; Chen, PY; Fang, YJ; Hsieh, TY; Huang, CS; Huang, KJ; Huang, YJ; Hwang, JJ; Kao, JH; Kao, WY; Lai, HC; Lee, FJ; Lee, PL; Liu, CH; Liu, CJ; Lo, CC; Peng, CY; Shih, YL; Su, PY; Su, WW; Tsai, MC; Tseng, CW; Tseng, KC; Wu, JH; Yang, SS1
Hou, MC; Huang, YH; Lan, KH; Lee, WP; Wang, YW1
Álvares-DA-Silva, MR; Dihl, RR; Librelotto, CS; Simon, D; Souza, AP1
Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H1
Abdel-Bary, HM; El Sayed, IET; Ghanm, SE; Othman Saad, W; Saad, BF; Shebl, NA1
Abd-Elsalam, S; AbdElrahman, M; Bader El Din, NG; Barakat, AZ; El Awady, MK; Elbatae, H; Farouk, S; Ibrahim, MK; Omran, D; Tawfik, S1
Li, J; Liu, J; Ma, HX; Wang, CY; Wen, J1
Nguyen, MH; Wong, YJ1
Al-Judaibi, B; Carleton, BC; Chang, WC; Crotty, P; Drögemöller, BI; Farivar, JF; Ford, JA; Kim, RB; Lee, SS; Li, KH; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJD; Schwarz, UI; Tam, E; Trueman, JN; Walston, LL; Wright, GEB; Yoshida, EM1
Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML1
AlBayati, SM; Faraj, OA1
Dai, L; He, Q; Liang, Z; Lu, F; Shu, J; Wang, L; Zhang, F1
Kao, JH; Liu, CH; Liu, CJ1
Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI1
Al-Dhamin, Z; An, J; Cui, L; Han, T; Hou, Y; Li, L; Li, W; Liang, J; Liu, L; Nan, Y; Xue, N; Zhang, L; Zhao, W1
A Wahsh, E; Ahmed, M; Ahmed, S; Elsayed, A; Esamat, G; Gomaa, A; Hassan, E; Ramadan, A1
Guo, M; Ke, L; Liu, J; You, R1
Ebell, M; Elshafie, S; Trivedi-Kapoor, R1
Rabarioely, SS; Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI1
Chang, YL; Hou, MC; Huang, YH; Lan, KH; Lee, WP; Lu, CL; Wang, YK; Wang, YW1
Akbulut, A; Akıncı, E; Bal, T; Barut, Ş; Batırel, A; Baykam, N; Çabalak, M; Can, G; Çelebi, G; Çuvalcı Öztoprak, N; Duygu, F; Erben, N; Esen Yıldız, İ; Esen, Ş; Gül, HC; Günal, Ö; Gündüz, A; Güner, R; Hızel, K; İnan, D; İnce, N; Karaali, R; Karabay, O; Karsen, H; Kaya, S; Köksal, İ; Kömür, S; Köse, Ş; Kumbasar Karaosmanoğlu, H; Kurtaran, B; Namıduru, M; Önlen, Y; Sarı, ND; Sarıgül Yıldırım, F; Şenateş, E; Şener, A; Sırmatel, F; Sünnetçioğlu, M; Tabak, F; Tosun, S; Türker, K; User, Ü; Yamazhan, T; Yörük, G; Zerdali, E1
Bishai, N; Fiki, ME; Garem, NE; Ibrahim, M; Nabawy, WE1
Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D1
Abdelghafour, R; AbdelRazek, W; Dabees, H; Said, M; Shousha, HI1
Fernandes, F; Pereira, G; Perez, R; Piedade, J; Victor, L; Villela-Nogueira, CA1
Abd El-Hameed, M; Dawood, RM; El Ray, AA; Mahmoud Diab, T; Mashaal, AR; Seyam, M; Shemis, MA1
Bearne, SL; Gillis, TD1
Fu, X; Guo, M; He, YQ; Li, CY; Qiao, M; Ren, XD1
Cordie, A; Esmat, G; Kamel, AM; Sabry, N1
Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J1
Gamil, AN; Hassuna, NA; Khairy, R; Mahmoud, MS; Mohamed, WK1
Ansari, MA; Barnes, E; Chau, NVV; Cooke, GS; Dang Trong, T; Day, JN; Flower, B; Hoglund, RM; Hung, LM; Kestelyn, E; Kingsley, C; Le Ngoc, C; Le Thi, T; Mccabe, L; Nguyen Bao, T; Nguyen Thi Ngoc, P; Pett, SL; Phuong, LT; Quang, VM; Rahman, M; Smith, D; Tarning, J; Thwaites, GE; Turner, H; van Doorn, R; Van Nuil, JI; Vo Thi, T; Vu Thi Kim, H; Walker, AS1
Hon, KLE; Leung, AKC; Sridhar, S; Wong, AHC1
Ahn, SH; Cho, SB; Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, S; Kim, YS; Lee, BS; Lee, S; Lee, YJ; Park, HJ1
Congly, SE; El-Kassas, M; El-Raey, F; Emadeldeen, M; Esmat, G; Gomaa, AA; Hassany, M; Lee, SS; Liu, H1
Cheng, ML; Li, H; Qin, YJ; Zhou, XN1
El-Marakby, MG; Sabri, NA; Solayman, MH1
Kottilil, S; Lee, MH; O'Brien, TR; Wilson, E1
Bukh, J; Fahnøe, U; Filskov, J; Jenssen, H; Pedersen, MS; Schønning, K; Sølund, C; Weis, N1
Briones, C; de Ávila, AI; Domingo, E; Durán-Pastor, A; Gallego, I; García-Crespo, C; Gómez, J; Gregori, J; Martínez-González, B; Perales, C; Quer, J; Somovilla, P; Soria, ME1
Al-Qahtani, SD; Alalawy, AI; Alatawi, K; El-Mehasseb, IM; El-Shafai, NM; Farrag, MA; Nada, AI1
Elmowafy, AY; Elrakaiby, MT; Mohamed Abdelnajid, D; Rostaing, L1
Coppola, N; Devan, P; Mohan, BP; Neo, JE; Preda, CM; Tam, YCS; Tiong, KLA; Wijarnpreecha, K; Wong, YJ1
Ahmad, B; Ahmad, J; Ahmad, L; Bashir, K; Chen, TW; Hameed, H; Haq, I; Haq, M; Hussain, K; M Aljowaie, R; Malik, G; Maryam, A; Mohsen Abougazia, E; Ullah, A1
Alsina, A; Borg, B; Chang, C; Charlton, M; Flamm, S; Hernandez, C; Hézode, C; Landis, C; Lawitz, E; Mercier, RC; Ravendhran, N; Reddy, KR; Samuel, D; Scherbakovsky, S; Shiffman, M1
Daryani, N; Imam, U; Mumtaz, F; Parkash, A1
Abdelmahmoud, MB; AlAlwan, AM; AlGhamdi, HS; AlHabobi, AA; Aljumah, AA; AlOun, AA; AlQahtani, RS; AlThiab, KM; AlTraif, IH; Ghomraoui, FA1

Reviews

88 review(s) available for sofosbuvir and ribavirin

ArticleYear
Drugs for the Treatment of Zika Virus Infection.
    Journal of medicinal chemistry, 2020, 01-23, Volume: 63, Issue:2

    Topics: Animals; Antiviral Agents; Drug Development; Drug Discovery; Humans; Viral Vaccines; Zika Virus; Zika Virus Infection

2020
Interferon free hepatitis C treatment regimens: the beginning of another era.
    Current gastroenterology reports, 2012, Volume: 14, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate

2012
What's new in HCV genotype 2 treatment.
    Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2012
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.
    Clinics in liver disease, 2013, Volume: 17, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate

2013
Emerging treatments for hepatitis C.
    Expert opinion on emerging drugs, 2013, Volume: 18, Issue:4

    Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2013
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Expert review of anti-infective therapy, 2013, Volume: 11, Issue:12

    Topics: Antiviral Agents; Biomarkers, Pharmacological; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2013
Treatment of hepatitis C virus genotype 3-infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins

2014
HCV direct-acting antiviral agents: the best interferon-free combinations.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication

2014
HCV F1/F2 patients: treat now or continue to wait.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate

2014
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Hepatitis C virus therapy in the direct acting antiviral era.
    Current opinion in gastroenterology, 2014, Volume: 30, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate

2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.
    Clinical pharmacokinetics, 2014, Volume: 53, Issue:5

    Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
The rapid evolution of treatment strategies for hepatitis C.
    The American journal of gastroenterology, 2014, Volume: 109, Issue:5

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2014
Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Aug-01, Volume: 59, Issue:3

    Topics: Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins

2014
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9

    Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Hepatitis C.
    Disease-a-month : DM, 2014, Volume: 60, Issue:5

    Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult

2014
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:7

    Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2014
Antiviral treatment of hepatitis C.
    BMJ (Clinical research ed.), 2014, Jul-07, Volume: 348

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Hepatitis C genotype 1.
    Current opinion in infectious diseases, 2014, Volume: 27, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load

2014
Update on the treatment of hepatitis C genotypes 2-6.
    Current opinion in infectious diseases, 2014, Volume: 27, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Load

2014
Recent advances in the treatment of hepatitis C.
    Discovery medicine, 2014, Volume: 18, Issue:99

    Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Hepatitis C management in post-transplant patients.
    Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load

2015
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:47

    Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2014
Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3

    Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins

2015
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine

2015
Optimal therapy of genotype-2 chronic hepatitis C: what's new?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prevalence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Optimal therapy in genotype 4 chronic hepatitis C: finally cured?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1

    Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins

2015
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Clinical therapeutics, 2015, Feb-01, Volume: 37, Issue:2

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nausea; Polyethylene Glycols; Protease Inhibitors; Ribavirin; Simeprevir; Sofosbuvir

2015
Management of post transplant hepatitis C in the direct antiviral agents era.
    Hepatology international, 2015, Volume: 9, Issue:2

    Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins

2015
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
    Transplant international : official journal of the European Society for Organ Transplantation, 2015, Volume: 28, Issue:9

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine

2015
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:9

    Topics: 2-Naphthylamine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil

2015
Therapy for hepatitis C genotype 3: moving forward.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:9

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Health Care Costs; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load

2015
Management of direct-acting antiviral agent failures.
    Journal of hepatology, 2015, Volume: 63, Issue:6

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine

2015
Ideal oral combinations to eradicate HCV: The role of ribavirin.
    Journal of hepatology, 2016, Volume: 64, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine

2016
Regimens for Patients Coinfected with Human Immunodeficiency Virus.
    Clinics in liver disease, 2015, Volume: 19, Issue:4

    Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; Polyethylene Glycols; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins

2015
Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
    Expert review of gastroenterology & hepatology, 2016, Volume: 10, Issue:1

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Transplantation; Recurrence; Renal Insufficiency; Ribavirin; Sofosbuvir

2016
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
    Expert review of gastroenterology & hepatology, 2015, Volume: 9, Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir

2015
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Disease Management; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2016
Hepatitis C virus: how to provide the best treatment with what I have.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult

2016
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Clinical therapeutics, 2016, Volume: 38, Issue:2

    Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, Volume: 67, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Republic of Korea; Ribavirin; Sofosbuvir

2016
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.
    World journal of gastroenterology, 2016, Jun-14, Volume: 22, Issue:22

    Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Odds Ratio; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Valine

2016
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Transplantation; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Daclatasvir: A Review in Chronic Hepatitis C.
    Drugs, 2016, Volume: 76, Issue:14

    Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
    Antiviral therapy, 2017, Volume: 22, Issue:5

    Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Publication Bias; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2017
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
    Drugs, 2016, Volume: 76, Issue:16

    Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2016, Oct-24, Volume: 49, Issue:11

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Databases, Bibliographic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation.
    Minerva gastroenterologica e dietologica, 2017, Volume: 63, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Tissue Donors; Viral Load

2017
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017, Volume: 55

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Hepatitis C: efficacy and safety in real life.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37 Suppl 1

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Randomized Controlled Trials as Topic; Renal Insufficiency; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Management of direct antiviral agent failures.
    Clinical and molecular hepatology, 2016, Volume: 22, Issue:4

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir

2016
Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis.
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:3

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:8

    Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load

2017
HCV management in resource-constrained countries.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine

2017
The Challenge of Treating Children With Hepatitis C Virus Infection.
    Journal of pediatric gastroenterology and nutrition, 2017, Volume: 64, Issue:6

    Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate

2017
Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2017, Apr-20, Volume: 25, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Sofosbuvir

2017
Sofosbuvir and velpatasvir for the treatment of hepatitis C.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:6

    Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Risk Factors; Sofosbuvir; Sustained Virologic Response; Viral Load

2017
Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
    Transplantation proceedings, 2017, Volume: 49, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2017
Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.
    BMC infectious diseases, 2017, 11-16, Volume: 17, Issue:1

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
    BMC gastroenterology, 2017, Nov-23, Volume: 17, Issue:1

    Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine

2017
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load

2018
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.
    Drugs, 2018, Volume: 78, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2018
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
    Clinical drug investigation, 2018, Volume: 38, Issue:5

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine

2018
Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
    Expert opinion on drug metabolism & toxicology, 2018, Volume: 14, Issue:9

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:1

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
    Medicina (Kaunas, Lithuania), 2018, Nov-05, Volume: 54, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Pakistan; Prevalence; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response

2018
Treatment of hepatitis C virus genotype 4 in the DAA era.
    Virology journal, 2018, 11-22, Volume: 15, Issue:1

    Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2018
Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2019, Feb-14, Volume: 61

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Viral Load

2019
Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis.
    Virology journal, 2019, 03-14, Volume: 16, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Prospective Studies; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2019, Volume: 83

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
    Seminars in liver disease, 2019, Volume: 39, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2019
Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.
    BioMed research international, 2019, Volume: 2019

    Topics: Antiviral Agents; Benzimidazoles; Databases, Factual; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Uridine Monophosphate

2019
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:8

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization

2020
Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
    Medicine, 2020, Oct-09, Volume: 99, Issue:41

    Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Middle Aged; Recurrence; Ribavirin; Sofosbuvir

2020
Treatment failure with DAA therapy: Importance of resistance.
    Journal of hepatology, 2021, Volume: 74, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2021
Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis.
    BMC infectious diseases, 2021, Sep-21, Volume: 21, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lipoproteins, LDL; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
    Frontiers in public health, 2022, Volume: 10

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides

2022
Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis.
    Medicine, 2022, Oct-21, Volume: 101, Issue:42

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation.
    Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Hepatitis E virus and Zoonosis: Recent Advances and Therapeutic Implications.
    Recent advances in inflammation & allergy drug discovery, 2023, Volume: 17, Issue:1

    Topics: Animals; Female; Hepatitis A; Hepatitis E; Hepatitis E virus; Humans; Pregnancy; Rats; Ribavirin; Sofosbuvir; Zoonoses

2023
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
    Therapeutic innovation & regulatory science, 2023, Volume: 57, Issue:5

    Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response

2023
Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
    Viruses, 2023, 06-30, Volume: 15, Issue:7

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2023

Trials

148 trial(s) available for sofosbuvir and ribavirin

ArticleYear
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.
    Journal of hepatology, 2013, Volume: 58, Issue:4

    Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult

2013
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
    The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins

2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult

2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate

2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
    The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult

2013
Sofosbuvir for previously untreated chronic hepatitis C infection.
    The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Young Adult

2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.
    JAMA, 2013, Aug-28, Volume: 310, Issue:8

    Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2013
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    The Journal of infectious diseases, 2014, Mar-01, Volume: 209, Issue:5

    Topics: Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
    Lancet (London, England), 2014, Feb-08, Volume: 383, Issue:9916

    Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).
    Journal of hepatology, 2014, Volume: 60, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Health; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
    The Journal of infectious diseases, 2014, Jun-01, Volume: 209, Issue:11

    Topics: Antiviral Agents; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
    The New England journal of medicine, 2014, Jan-16, Volume: 370, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Young Adult

2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
    Journal of hepatology, 2014, Volume: 61, Issue:2

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
    The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult

2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult

2014
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    The New England journal of medicine, 2014, May-22, Volume: 370, Issue:21

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2014
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:8

    Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Endopeptidases; Gene Expression; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Recurrence; Ribavirin; RNA, Messenger; Sofosbuvir; Treatment Outcome; Ubiquitin Thiolesterase; Uridine Monophosphate

2014
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6

    Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Health Surveys; Hepatitis C, Chronic; Humans; Interferons; Male; Patient Preference; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Uridine Monophosphate

2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lancet (London, England), 2014, Nov-15, Volume: 384, Issue:9956

    Topics: Adult; Antiviral Agents; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2014
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Drug Resistance, Viral; Female; Fluorenes; Furans; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Binding; Quinolines; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
    Journal of viral hepatitis, 2014, Volume: 21, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult

2014
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3

    Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Virus Replication

2015
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Gastroenterology, 2015, Volume: 148, Issue:1

    Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists

2015
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Gastroenterology, 2015, Volume: 148, Issue:1

    Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2015
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
    Annals of internal medicine, 2014, Nov-04, Volume: 161, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate

2014
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Treatment Outcome; United States; Viral Load; Viral Nonstructural Proteins

2015
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5

    Topics: Antiviral Agents; Compassionate Use Trials; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Failure; Uridine Monophosphate

2015
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Gastroenterology, 2015, Volume: 148, Issue:4

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load

2015
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
    The Journal of infectious diseases, 2015, Aug-01, Volume: 212, Issue:3

    Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Quality of Life; Ribavirin; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load

2015
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.
    Journal of acquired immune deficiency syndromes (1999), 2015, Apr-15, Volume: 68, Issue:5

    Topics: Adult; Aged; Animals; Anti-Retroviral Agents; Antiviral Agents; Cohort Studies; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2015
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult

2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Double-Blind Method; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebos; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult

2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate

2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult

2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate; Young Adult

2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
    The Lancet. Infectious diseases, 2015, Volume: 15, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult

2015
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Young Adult

2015
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:8

    Topics: Adult; Aged; Anemia; Antiviral Agents; Erythrocytes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Serum; Sofosbuvir; Treatment Outcome; Viral Load

2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Gastroenterology, 2015, Volume: 149, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate

2015
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:11

    Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2015
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; RNA, Viral; Sofosbuvir

2016
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Adult; Antiviral Agents; Benzimidazoles; Chemokine CXCL10; Convalescence; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Protein Processing, Post-Translational; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Virus Replication

2015
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2015
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; New Zealand; Random Allocation; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2015
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
    Journal of viral hepatitis, 2015, Volume: 22, Issue:12

    Topics: Antiviral Agents; Apolipoproteins; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2015
Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hong Kong; Humans; Male; Middle Aged; Ribavirin; RNA; Sofosbuvir; Treatment Outcome

2016
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Annals of internal medicine, 2015, Dec-01, Volume: 163, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Young Adult

2015
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    AIDS research and human retroviruses, 2016, Volume: 32, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate

2016
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.
    Annals of the rheumatic diseases, 2016, Volume: 75, Issue:10

    Topics: Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis

2016
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
    The New England journal of medicine, 2015, Dec-31, Volume: 373, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2015
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Valine

2016
Ocular Surface Changes With Sofosbuvir in Egyptian Patients With Hepatitis C Virus Infection.
    Cornea, 2016, Volume: 35, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Dry Eye Syndromes; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Tears

2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
    Journal of the American Geriatrics Society, 2016, Volume: 64, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:2

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Gastroenterology; Genotype; Graft vs Host Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Load

2016
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome; Viral Load; Young Adult

2016
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Young Adult

2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
    Antiviral therapy, 2016, Volume: 21, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load

2016
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
    Journal of hepatology, 2016, Volume: 65, Issue:1

    Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Patient Reported Outcome Measures; Quality of Life; Ribavirin; Sofosbuvir

2016
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Reported Outcome Measures; Retrospective Studies; Ribavirin; Sofosbuvir

2016
[Daclatasvir/sofosbuvir is effective also in advanced liver disease].
    MMW Fortschritte der Medizin, 2016, Mar-31, Volume: 158, Issue:6

    Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Veterans

2017
[In HIV-HCV co-infection check for drug interactions].
    MMW Fortschritte der Medizin, 2016, Jun-09, Volume: 158 Suppl 1

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
    Gastroenterology, 2016, Volume: 151, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins

2016
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:10

    Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2016
Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
    Antiviral therapy, 2016, Volume: 21, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2016
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 10-15, Volume: 63, Issue:8

    Topics: Adult; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2016
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.
    Canadian journal of gastroenterology & hepatology, 2016, Volume: 2016

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Gastroenterology, 2016, Volume: 151, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
    Journal of hepatology, 2016, Volume: 65, Issue:6

    Topics: Antiviral Agents; Benzofurans; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir

2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Dec-01, Volume: 63, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Data Interpretation, Statistical; Drug Therapy, Combination; Drug Users; Enzyme-Linked Immunosorbent Assay; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Opiate Substitution Treatment; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load

2016
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Dec-01, Volume: 63, Issue:11

    Topics: Adult; Antiviral Agents; Carbamates; Data Interpretation, Statistical; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:6

    Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Tacrolimus; Transaminases; Valine

2016
Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Adult; Antiviral Agents; Asian People; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome

2017
Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2016, Volume: 35, Issue:6

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO).
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2017
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
    BMC infectious diseases, 2017, 01-07, Volume: 17, Issue:1

    Topics: Antiviral Agents; Bayes Theorem; Carbamates; Cohort Studies; Drug Therapy, Combination; Europe; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity.
    Medicine, 2017, Volume: 96, Issue:7

    Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome; Work Performance

2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult

2017
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 04-15, Volume: 64, Issue:8

    Topics: Adult; Antiviral Agents; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    The lancet. Gastroenterology & hepatology, 2016, Volume: 1, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Intention to Treat Analysis; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2016
Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Infectious disorders drug targets, 2017, Volume: 17, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir

2017
Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jul-01, Volume: 65, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2017
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:4

    Topics: Adolescent; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2017
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Thalassemia; Treatment Failure; Uridine Monophosphate

2017
Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    Journal of viral hepatitis, 2018, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult

2018
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
    Journal of viral hepatitis, 2018, Volume: 25, Issue:2

    Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine

2018
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 03-19, Volume: 66, Issue:7

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2018
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Fatigue; Female; Fluorenes; Headache; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Pregnancy; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2018
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:4

    Topics: Antiviral Agents; Carbamates; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2018
IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Immunologic Factors; Interferon Type I; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:4

    Topics: Adolescent; Antiviral Agents; Child; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome

2018
The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:7

    Topics: Adult; Antiviral Agents; Asia, Eastern; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Linear Models; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Ribavirin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Time Factors

2018
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    Journal of hepatology, 2018, Volume: 68, Issue:4

    Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2018
Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2018
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Asian People; China; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2018
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:2

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome

2018
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus.
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:5

    Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Liver; Male; Mass Spectrometry; Middle Aged; Ribavirin; Sofosbuvir

2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzofurans; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sofosbuvir

2018
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents.
    Journal of internal medicine, 2018, Volume: 283, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Iceland; Incidence; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Needle-Exchange Programs; Population Surveillance; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate

2018
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
    Clinical pharmacokinetics, 2018, Volume: 57, Issue:11

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine; Young Adult

2018
Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:3

    Topics: Antiviral Agents; Gene Expression Profiling; Gene Expression Regulation; Genotype; Hepatitis C; Humans; Interleukins; Liver; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response

2018
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
    Digestive diseases and sciences, 2018, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2018
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    Journal of hepatology, 2018, Volume: 68, Issue:6

    Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine

2018
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:4

    Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2018
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut, 2019, Volume: 68, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2019
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate

2018
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Gastroenterology, 2018, Volume: 155, Issue:4

    Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug Resistance, Bacterial; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2018
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcome

2018
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load

2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Hepatology international, 2018, Volume: 12, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult

2018
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Child; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2018
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    Journal of gastroenterology, 2019, Volume: 54, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
    Infectious disorders drug targets, 2019, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:3

    Topics: Antiviral Agents; Biopsy; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kupffer Cells; Liver; Parenchymal Tissue; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies.
    Drug and alcohol dependence, 2019, 01-01, Volume: 194

    Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.
    Journal of medical virology, 2019, Volume: 91, Issue:7

    Topics: Adult; Antiviral Agents; Asian People; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult

2019
Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:9

    Topics: Adult; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Severity of Illness Index; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Uridine Monophosphate

2019
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.
    Cells, 2019, 04-04, Volume: 8, Issue:4

    Topics: Adult; Aged; Carbamates; Cohort Studies; Comorbidity; Female; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2019
Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2019
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 07-18, Volume: 69, Issue:3

    Topics: Acute Disease; Administration, Oral; Adult; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Administration Schedule; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load

2019
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
    Journal of hepatology, 2019, Volume: 71, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Clinical Protocols; Delivery of Health Care; Disease Eradication; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; India; Liver Cirrhosis; Male; Public Health; Ribavirin; Sofosbuvir; Sustained Virologic Response; Telemedicine

2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2019
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:2

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
    Gastroenterology, 2019, Volume: 157, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2019
SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 05-06, Volume: 70, Issue:10

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Iran; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tablets; Treatment Outcome; Valine

2020
Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study.
    Scientific reports, 2019, 09-19, Volume: 9, Issue:1

    Topics: Adult; Catechin; Daclizumab; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Random Allocation; Ribavirin; Sofosbuvir; Standard of Care; Sustained Virologic Response; Tablets; Treatment Outcome; Viral Load

2019
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life exp
    Archives of virology, 2020, Volume: 165, Issue:7

    Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine

2020
The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
    Trials, 2020, May-18, Volume: 21, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Bayes Theorem; Carbamates; Drug Monitoring; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Vietnam

2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; New Zealand; Non-Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Ribavirin; Safety; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2020
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
    The Journal of antimicrobial chemotherapy, 2020, 11-01, Volume: 75, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Hospitalization; Humans; Imidazoles; Iran; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine

2020
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
    The Journal of antimicrobial chemotherapy, 2020, 11-01, Volume: 75, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Betacoronavirus; Carbamates; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrrolidines; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Valine

2020
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.
    BMC infectious diseases, 2020, Dec-04, Volume: 20, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Longitudinal Studies; Male; Neutrophils; Recurrence; Ribavirin; Sofosbuvir; T-Lymphocytes; Transcriptome; Treatment Outcome

2020
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Patient-Centered Care; Ribavirin; Sofosbuvir; Sustained Virologic Response

2022
Novel combined single dose anti-hepatitis C therapy: a pilot study.
    Scientific reports, 2021, 02-25, Volume: 11, Issue:1

    Topics: Adult; Antiviral Agents; Catechin; Female; Genotype; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Ribavirin; Sofosbuvir

2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:6

    Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine; Young Adult

2021
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
    Journal of medicine and life, 2022, Volume: 15, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2022
Comparative Real Life Egyptian Experience of the Combination of Sofosbuvir Plus Daclatasvir or Simeprevir for 12 Weeks in Naïve Cirrhotic Patients Infected with HCV Genotype 4.
    Current drug safety, 2023, Volume: 18, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2023
A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
    Journal of hepatology, 2023, Volume: 79, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients.
    Pakistan journal of pharmaceutical sciences, 2023, Volume: 36, Issue:3(Special)

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response

2023

Other Studies

555 other study(ies) available for sofosbuvir and ribavirin

ArticleYear
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
    Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21

    Topics: Antiviral Agents; Cell Line; Deoxyadenosines; Deoxyribonucleosides; Halogenation; Hepacivirus; Hepatitis C; Humans; Structure-Activity Relationship

2014
2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
    Journal of medicinal chemistry, 2020, 06-11, Volume: 63, Issue:11

    Topics: Administration, Oral; Animals; Antiviral Agents; Cell Line; Dogs; Drug Design; Drug Resistance, Viral; Female; Half-Life; Hepacivirus; Humans; Male; Mice; Mutation; Nitriles; Rats; Structure-Activity Relationship; Virus Replication

2020
Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.
    ACS medicinal chemistry letters, 2020, May-14, Volume: 11, Issue:5

    Topics:

2020
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
    European journal of medicinal chemistry, 2021, Nov-15, Volume: 224

    Topics: Antiviral Agents; Flavivirus; Molecular Targeted Therapy; Orthomyxoviridae; Purines; SARS-CoV-2; Virus Replication

2021
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Sofosbuvir: the final nail in the coffin for hepatitis C?
    The Lancet. Infectious diseases, 2013, Volume: 13, Issue:5

    Topics: Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2013
Hepatitis C treatment: interferon free or interferon freer?
    Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate

2013
HCV treatment--no more room for interferonologists?
    The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2013
Interferon-free hepatitis C treatment: one pill to fit all?
    Lancet (London, England), 2014, Feb-08, Volume: 383, Issue:9916

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins

2014
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:8

    Topics: Antiviral Agents; Efficiency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome; Uridine Monophosphate

2014
Sofosbuvir approved for chronic hepatitis C infection.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Jan-15, Volume: 71, Issue:2

    Topics: Drug Approval; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate

2014
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:7

    Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine

2014
Hepatitis C treatment & management.
    Journal of medicine and life, 2014, Mar-15, Volume: 7, Issue:1

    Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate

2014
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Liver Cirrhosis; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Retreatment; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
The price of good health.
    Nature medicine, 2014, Volume: 20, Issue:4

    Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:6

    Topics: Adult; Antiviral Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
    Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate

2014
Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
    Seminars in liver disease, 2014, Volume: 34, Issue:1

    Topics: Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1

    Topics: Drug Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
My treatment approach to chronic hepatitis C virus.
    Mayo Clinic proceedings, 2014, Volume: 89, Issue:7

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2014
Hepatitis C: Treatment triumphs.
    Nature, 2014, Jun-05, Volume: 510, Issue:7503

    Topics: Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
[Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
    MMW Fortschritte der Medizin, 2014, Feb-20, Volume: 156, Issue:3

    Topics: Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2014
Elimination on the agenda for hepatitis C.
    The Lancet. Infectious diseases, 2014, Volume: 14, Issue:6

    Topics: Antiviral Agents; Disease Eradication; Global Health; Hepatitis C; Humans; Injections; Interferons; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate

2014
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschritte der Medizin, 2014, Jun-12, Volume: 156 Suppl 1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Secondary Prevention; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Female; Genome, Viral; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Phylogeny; Recombination, Genetic; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins

2015
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2015, Volume: 28, Issue:2

    Topics: Aged; Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Waiting Lists

2015
Mutant Ninja viruses.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
    Annals of internal medicine, 2014, Oct-21, Volume: 161, Issue:8

    Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Proline; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate

2014
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:2

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2015
Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Lipid Metabolism; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1

    Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:3

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Remission Induction; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Waiting Lists

2015
Viral hepatitis: cure of chronic hepatitis C--required length of follow-up?
    Nature reviews. Gastroenterology & hepatology, 2015, Volume: 12, Issue:1

    Topics: Antiviral Agents; Continuity of Patient Care; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better.
    Gastroenterology, 2015, Volume: 148, Issue:1

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Global public health, 2015, Volume: 10, Issue:3

    Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
    Therapeutic drug monitoring, 2015, Volume: 37, Issue:4

    Topics: Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2015
[Is more expensive always better?].
    Nederlands tijdschrift voor geneeskunde, 2014, Volume: 159

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Sofosbuvir; Uridine Monophosphate

2014
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:7

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Eligibility Determination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitalization; Humans; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Prospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome

2015
Shorter treatments for hepatitis C: another step forward?
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Furans; Hepatitis C, Chronic; Humans; Male; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Uridine Monophosphate

2015
[Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].
    MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2014
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
    Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
What is the role of sofosbuvir in treating hepatitis C infection?
    JAAPA : official journal of the American Academy of Physician Assistants, 2015, Volume: 28, Issue:2

    Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Ribavirin; Sofosbuvir

2015
Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2015, Volume: 21, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hemophilia A; Hepatitis C; HIV Infections; Humans; Liver Failure; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2015
PHOTON-2: hope for patients with HIV and HCV co-infection?
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate

2015
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
    Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6

    Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate

2015
[A new era in therapy of chronic hepatitis C].
    MMW Fortschritte der Medizin, 2015, Feb-05, Volume: 157, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2015
[New combination therapy increases chances of recovery].
    MMW Fortschritte der Medizin, 2015, Feb-19, Volume: 157, Issue:3

    Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2015
Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.
    Journal of hepatology, 2015, Volume: 62, Issue:5

    Topics: Benzazepines; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Interferon-alpha; Isoquinolines; Male; Polyethylene Glycols; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides

2015
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine

2015
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jul-15, Volume: 61, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; United States; Uridine Monophosphate; Young Adult

2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
    Annals of internal medicine, 2015, May-05, Volume: 162, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate

2015
Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:6

    Topics: Antiviral Agents; Carbamates; Hepacivirus; Imidazoles; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Valine; Viral Nonstructural Proteins

2015
Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment.
    Blood, 2015, Apr-09, Volume: 125, Issue:15

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate

2015
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
    BMC gastroenterology, 2015, Mar-26, Volume: 15

    Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recurrence; Reoperation; Ribavirin; Sofosbuvir

2015
Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.
    Journal of medical economics, 2015, Volume: 18, Issue:9

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Markov Chains; Patient Acceptance of Health Care; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Severity of Illness Index; Sofosbuvir

2015
Hepatitis C in Arkansas: updates on epidemiology, testing and treatment.
    The Journal of the Arkansas Medical Society, 2015, Volume: 111, Issue:12

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Arkansas; Cross-Sectional Studies; Drug Costs; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult

2015
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
    The American journal of psychiatry, 2015, Volume: 172, Issue:6

    Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Mianserin; Middle Aged; Mirtazapine; Physician's Role; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2015
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:3

    Topics: Aged; Analysis of Variance; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Safety; Reference Values; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Treatment Outcome

2015
The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:3

    Topics: Adult; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Mental Health; Middle Aged; Prospective Studies; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Withholding Treatment

2015
Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.
    European journal of clinical pharmacology, 2015, Volume: 71, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Interactions; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Ribavirin; Simeprevir; Sofosbuvir; Substance Withdrawal Syndrome

2015
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome; Viral Load

2015
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:4

    Topics: Antiviral Agents; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir

2015
Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Veterans

2015
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
    Journal of gastrointestinal and liver diseases : JGLD, 2015, Volume: 24, Issue:2

    Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Valine; Viral Load; Virus Activation

2015
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.
    Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:4

    Topics: Antiviral Agents; Case-Control Studies; Chemokines; Cytokines; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors

2015
Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
    Clinical transplantation, 2015, Volume: 29, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholestasis, Intrahepatic; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Matched-Pair Analysis; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2015
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2015
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2015
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2015, Volume: 69

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Treatment Failure; Treatment Outcome

2015
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
    The American journal of gastroenterology, 2015, Volume: 110, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Hyperbilirubinemia; Intention to Treat Analysis; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sepsis; Simeprevir; Sofosbuvir; Sulfonamides; Time Factors; Uridine Monophosphate

2015
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
    BMC infectious diseases, 2015, Jul-30, Volume: 15

    Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Proline; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2015
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
    BMC gastroenterology, 2015, Aug-05, Volume: 15

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate

2015
Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    BMC gastroenterology, 2015, Aug-04, Volume: 15

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult

2015
Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2016, Volume: 14, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Biomarkers; Blood Chemical Analysis; Cytokines; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.
    Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Ultrasonography; Uridine Monophosphate; Valine

2015
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals?
    Journal of hepatology, 2015, Volume: 63, Issue:5

    Topics: Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir

2015
The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin.
    Antiviral therapy, 2016, Volume: 21, Issue:2

    Topics: Antiviral Agents; Drug Inverse Agonism; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir

2016
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
    Journal of hepatology, 2016, Volume: 64, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins

2016
Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Texas; Time Factors; Treatment Outcome

2016
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
    Journal of hepatology, 2016, Volume: 64, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir

2016
Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Oct-01, Volume: 1002

    Topics: Animals; Antiviral Agents; Calibration; Chromatography, Liquid; Limit of Detection; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Ribavirin; Sofosbuvir; Tandem Mass Spectrometry

2015
Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.
    Infectious diseases (London, England), 2015, Volume: 47, Issue:12

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load

2015
Antihepatitis C virus treatments for HIV-hepatitis C virus coinfected cirrhotic patients: a need to look beyond the sustained viral response.
    AIDS (London, England), 2015, Sep-10, Volume: 29, Issue:14

    Topics: Antiviral Agents; Coinfection; Fatal Outcome; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load

2015
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.
    Journal of comparative effectiveness research, 2016, Volume: 5, Issue:2

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Standard of Care; Treatment Outcome; Valine

2016
Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
    Annals of transplantation, 2015, Sep-22, Volume: 20

    Topics: Antiviral Agents; Female; Graft Survival; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2015
Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
    Gastroenterology, 2016, Volume: 150, Issue:1

    Topics: Antiviral Agents; Chronic Disease; Drug Synergism; Drug Therapy, Combination; Hepatitis E; Hepatitis E virus; Humans; In Vitro Techniques; Ribavirin; RNA, Viral; Sofosbuvir; Virus Replication

2016
Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?
    Gastroenterology, 2015, Volume: 149, Issue:6

    Topics: Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir

2015
Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:12

    Topics: Aged; Aged, 80 and over; Antiviral Agents; California; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Male; Medically Underserved Area; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir

2015
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir

2016
Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Stem Cell Transplantation; Transplant Recipients; Transplantation, Homologous; Viral Load; Virus Replication

2016
Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Viral Core Proteins; Viral Load

2016
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
    Gastroenterology, 2016, Volume: 150, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; North America; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load; Young Adult

2016
Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States

2016
Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
    Journal of hepatology, 2016, Volume: 64, Issue:4

    Topics: Acidosis, Lactic; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir

2016
Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    PharmacoEconomics, 2016, Volume: 34, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Markov Chains; Models, Statistical; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; South Africa; Uridine Monophosphate

2016
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Patient Safety; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Assessment; Sex Factors; Sofosbuvir; Treatment Outcome

2016
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Antiviral research, 2016, Volume: 126

    Topics: Adenosine; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Oligopeptides; Protease Inhibitors; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins; Virus Replication

2016
Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
    Journal of digestive diseases, 2016, Volume: 17, Issue:2

    Topics: Aged; Antiviral Agents; Community Health Services; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection.
    Journal of pharmacy practice, 2017, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Utilization; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult

2017
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2015
The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:7

    Topics: Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load

2016
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C.
    Journal of hepatology, 2016, Volume: 64, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate

2016
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5.
    The Lancet. Infectious diseases, 2016, Volume: 16, Issue:4

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate

2016
A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:4

    Topics: Antiviral Agents; Base Sequence; Binding Sites; Cloning, Molecular; Escherichia coli; Gene Expression; Hepacivirus; Hydrogen Bonding; Microbial Sensitivity Tests; Mutation; Protein Binding; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Viral Nonstructural Proteins

2016
Letter: self-pay behaviour patients with chronic hepatitis C who required direct acting anti-viral urgently in a real-world setting.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:6

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir

2016
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:4

    Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2016
Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:5

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Polymorphism, Genetic; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome

2016
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2017
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9

    Topics: Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Medication Adherence; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Veterans

2016
Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:7

    Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir

2016
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
    Transplantation, 2016, Volume: 100, Issue:5

    Topics: Aged; Antiviral Agents; Biopsy; Canada; Creatinine; Female; Fibrosis; Genotype; Glomerular Filtration Rate; Hepatitis C; Humans; Interferons; Kidney; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir

2016
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
    Journal of hepatology, 2016, Volume: 65, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prospective Studies; Renal Dialysis; Ribavirin; Simeprevir; Sofosbuvir

2016
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.
    Chest, 2016, Volume: 149, Issue:3

    Topics: Antiviral Agents; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    World journal of gastroenterology, 2016, Mar-07, Volume: 22, Issue:9

    Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation

2016
Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:3

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
    Clinical transplantation, 2016, Volume: 30, Issue:6

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult

2016
Sofosbuvir plus ribavirin in Asian patients with chronic genotype 2 hepatitis C virus infection: history of a success?
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:8

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2016
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Journal of medical economics, 2016, Volume: 19, Issue:8

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine

2016
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
    Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:12

    Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine

2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 08-15, Volume: 63, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure

2016
Resurrection of response-guided therapy for sofosbuvir combination therapies.
    Journal of hepatology, 2016, Volume: 65, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2016
Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.
    Journal of hepatology, 2016, Volume: 65, Issue:4

    Topics: Antiviral Agents; Compassionate Use Trials; Drug Therapy, Combination; France; Hepacivirus; Hepatitis C; Humans; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.
    BMJ case reports, 2016, Jun-09, Volume: 2016

    Topics: Benzimidazoles; Cryoglobulinemia; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2016
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:4

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult

2016
Drug Pricing Evolution in Hepatitis C.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Discovery; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Oligopeptides; Ribavirin; Ritonavir; Sofosbuvir; Switzerland; United States

2016
Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
    Infection, 2016, Volume: 44, Issue:6

    Topics: Aged; Antiviral Agents; Colitis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Simeprevir; Sofosbuvir

2016
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 09-15, Volume: 63, Issue:6

    Topics: Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2016
Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients.
    The Netherlands journal of medicine, 2016, Volume: 74, Issue:5

    Topics: Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load

2016
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 09-15, Volume: 63, Issue:6

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult

2016
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Antiviral therapy, 2017, Volume: 22, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate

2017
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Advances in therapy, 2016, Volume: 33, Issue:8

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine

2016
Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:1

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2017
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
    The American journal of managed care, 2016, 06-01, Volume: 22, Issue:6

    Topics: Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance Claim Review; Interferons; Logistic Models; Male; Middle Aged; Oligopeptides; Predictive Value of Tests; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; United States

2016
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report.
    Annals of transplantation, 2016, Jun-30, Volume: 21

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Failure; Liver Transplantation; Oligopeptides; Postoperative Complications; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2016
Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2016, Volume: 49

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2016
Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.
    BMC gastroenterology, 2016, Jul-11, Volume: 16, Issue:1

    Topics: Antiviral Agents; Colitis, Ulcerative; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2016
IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
    The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:11

    Topics: Adult; Antiviral Agents; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome

2016
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome

2016
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Gut, 2017, Volume: 66, Issue:10

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Young Adult

2017
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
    Medicine, 2016, Volume: 95, Issue:28

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir

2016
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Prospective Studies; Registries; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult

2017
Oral therapy approved for chronic HCV infection of all genotypes.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Aug-01, Volume: 73, Issue:15

    Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir

2016
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2016, Volume: 82

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins

2016
Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:7

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Veterans

2016
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin".
    Journal of hepatology, 2016, Volume: 65, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2016
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin.
    Journal of hepatology, 2016, Volume: 65, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Kinetics; Ribavirin; RNA; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2016
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:5

    Topics: Aged; Antiviral Agents; B-Lymphocytes; Cryoglobulinemia; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Practice Guidelines as Topic; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Vasculitis

2016
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Models, Economic; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate

2017
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Time Factors; Tissue Donors; Treatment Outcome; Uridine Monophosphate

2017
Sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C infection: Impact of drug concentration on viral load decay.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:11

    Topics: Aged; Antiviral Agents; Carbamates; Drug Monitoring; Drug Therapy, Combination; Female; France; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load

2016
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
    Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Interactions; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
    Medicine, 2016, Volume: 95, Issue:33

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires

2016
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:11

    Topics: Aged; Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Pragmatic Clinical Trials as Topic; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Uridine Monophosphate

2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Gastroenterology, 2016, Volume: 151, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Bilirubin; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ribavirin; Risk Factors; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Failure; Uridine Monophosphate; Young Adult

2016
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity?
    The American journal of gastroenterology, 2016, Volume: 111, Issue:9

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Photosensitivity Disorders; Porphyrins; Recurrence; Ribavirin; Simeprevir; Sofosbuvir

2016
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.
    Gut, 2016, Volume: 65, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Compassionate Use Trials; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Failure; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine

2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Journal of hepatology, 2017, Volume: 66, Issue:1

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; France; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2017
Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:4

    Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2017
Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy.
    Antiviral therapy, 2017, Volume: 22, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load

2017
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
    Alimentary pharmacology & therapeutics, 2016, Volume: 44, Issue:10

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States

2016
Ushering in an Era Where No Group Who Wants to Be Treated Should Be Excluded.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:2

    Topics: Genotype; Hepacivirus; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Veterans

2017
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    World journal of gastroenterology, 2016, Sep-21, Volume: 22, Issue:35

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2016
Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.
    Journal of hepatology, 2017, Volume: 66, Issue:1

    Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis E; Hepatitis E virus; Hepatitis, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2017
Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Pharmacotherapy, 2016, Volume: 36, Issue:11

    Topics: Aged; Anticoagulants; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Veterans; Warfarin

2016
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult

2017
Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Pyrrolidines; Retrospective Studies; Ribavirin; San Francisco; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Vulnerable Populations; Young Adult

2016
Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in HCV genotype IV infected patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2017
The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Asian; Black People; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Ethnicity; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prognosis; Racial Groups; Ribavirin; Risk Assessment; Simeprevir; Sofosbuvir; Survival Rate; Treatment Outcome; United States; White People

2017
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2017
Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection.
    The New England journal of medicine, 2016, Oct-27, Volume: 375, Issue:17

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lymphoma, Follicular; Male; Ribavirin; Sofosbuvir; Viral Load

2016
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis.
    Antiviral research, 2016, Volume: 136

    Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Failure; Treatment Outcome

2016
All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:1

    Topics: Administration, Oral; Adult; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir

2017
HCV-associated cryoglobulinemia vasculitis: are its days numbered?
    Annals of the rheumatic diseases, 2017, Volume: 76, Issue:3

    Topics: Cryoglobulinemia; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Vasculitis

2017
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Decision Making; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Markov Chains; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate

2017
Regression of hepatocellular carcinoma after treatment with Sofosbuvir - A case report.
    JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:11

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome

2016
ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.
    Journal of gastroenterology, 2017, Volume: 52, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology, 2017, Volume: 152, Issue:3

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication

2017
Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Antiviral therapy, 2017, Volume: 22, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Load

2017
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2017, Volume: 15, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Treatment Outcome

2017
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
    Medicine, 2016, Volume: 95, Issue:46

    Topics: Affective Symptoms; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Mental Disorders; Middle Aged; Neurotransmitter Agents; Retrospective Studies; Ribavirin; Sofosbuvir

2016
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
    Transplantation, 2017, Volume: 101, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Models, Economic; Postoperative Care; Preoperative Care; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate

2017
Sofosbuvir and ribavirin in acute hepatitis C-infected patient with decompensated cirrhosis.
    Medicine, 2016, Volume: 95, Issue:49

    Topics: Administration, Oral; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2016
Hepatitis C Virus in Kidney Transplant Recipients: A Problem on the Path to Eradication.
    Transplantation proceedings, 2016, Volume: 48, Issue:9

    Topics: Adult; Antiviral Agents; Female; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Ribavirin; Sofosbuvir; Tacrolimus

2016
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
    Transplantation proceedings, 2016, Volume: 48, Issue:9

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine

2016
Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
    Transplantation proceedings, 2016, Volume: 48, Issue:9

    Topics: Antiviral Agents; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Treatment Outcome

2016
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2017
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
    Antiviral research, 2017, Volume: 138

    Topics: Adenosine Triphosphate; Anemia, Hemolytic; Female; Guanosine Triphosphate; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Inosine Triphosphate; Male; Middle Aged; Nucleotides; Phenotype; Polymorphism, Single Nucleotide; Purines; Pyrophosphatases; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.
    Journal of hepatology, 2017, Volume: 66, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recombination, Genetic; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Young Adult

2017
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2017, Volume: 23, Issue:4

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2017
Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2018, Volume: 19, Issue:1

    Topics: Antiviral Agents; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
    Antiviral therapy, 2017, Volume: 22, Issue:3

    Topics: Alleles; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins

2017
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
    Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2017
Genotype specific peripheral lipid profile changes with hepatitis C therapy.
    World journal of gastroenterology, 2016, Dec-14, Volume: 22, Issue:46

    Topics: Aged; Alanine Transaminase; Antiviral Agents; Benzimidazoles; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Triglycerides

2016
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:2

    Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load

2017
Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir

2017
HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy.
    Antiviral therapy, 2017, Volume: 22, Issue:4

    Topics: Alanine Transaminase; Antiviral Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Middle Aged; Phylogeny; Reassortant Viruses; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Failure

2017
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:4

    Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2017
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Antiviral Agents; Asian People; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Pyrophosphatases; Ribavirin; Sofosbuvir

2017
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2017, Volume: 23, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2017
Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    PloS one, 2017, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Belgium; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Treatment Outcome

2017
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    Journal of gastroenterology, 2017, Volume: 52, Issue:8

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins

2017
Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.
    Health and quality of life outcomes, 2017, Jan-31, Volume: 15, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Psychometrics; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome

2017
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
    International journal of antimicrobial agents, 2017, Volume: 49, Issue:3

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Italy; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
    Journal of medical virology, 2017, Volume: 89, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antigens, Neoplasm; Antiviral Agents; Drug Monitoring; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Membrane Glycoproteins; Middle Aged; Prognosis; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Withholding Treatment

2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cause of Death; Cohort Studies; Disease Progression; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Spain; Survival Analysis; Treatment Outcome

2017
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2017
Sofosbuvir in the treatment of early HCV infection in HIV-infected men.
    HIV clinical trials, 2017, Volume: 18, Issue:2

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Mutation; Pilot Projects; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load

2017
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Journal of hepatology, 2017, Volume: 66, Issue:6

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult

2017
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
    Journal of hepatology, 2017, Volume: 66, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; China; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Medical Tourism; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Therapeutic Equivalency; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jun-15, Volume: 64, Issue:12

    Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans

2017
Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, Mar-01, Volume: 74, Issue:5 Suppleme

    Topics: Aged; Ambulatory Care; Ambulatory Care Facilities; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2017
Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:Suppl 1

    Topics: Adult; Antiviral Agents; Developing Countries; Drug Therapy, Combination; Female; Genotype; Health Resources; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pakistan; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load; Young Adult

2017
Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report.
    Annals of internal medicine, 2017, 03-07, Volume: 166, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Ribavirin; Sofosbuvir; Spinal Cord Diseases; Viral Load

2017
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Scandinavian journal of gastroenterology, 2017, Volume: 52, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sweden; Treatment Outcome; Valine

2017
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
    Journal of acquired immune deficiency syndromes (1999), 2017, 05-01, Volume: 75, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2017
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
    Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3

    Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Valine

2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Gastroenterology, 2017, Volume: 152, Issue:8

    Topics: Aged; Antiviral Agents; B-Lymphocyte Subsets; Biomarkers; Carbamates; Case-Control Studies; Cryoglobulinemia; Cytokines; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis Viruses; Humans; Imidazoles; Immune Tolerance; Immunity, Cellular; Male; Middle Aged; Phenotype; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; T-Lymphocyte Subsets; Time Factors; Treatment Outcome; Valine; Vasculitis; Viral Load

2017
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:6

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Ireland; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Program Evaluation; Prospective Studies; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate

2017
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
    Recenti progressi in medicina, 2017, Volume: 108, Issue:2

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine

2017
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Journal of gastroenterology, 2017, Volume: 52, Issue:10

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine

2017
Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.
    World journal of gastroenterology, 2017, Mar-07, Volume: 23, Issue:9

    Topics: Analgesics; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacists; Pharmacy; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2017
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine

2017
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Nephrology (Carlton, Vic.), 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load

2018
Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:2

    Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Adult; Antiviral Agents; Asia; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA Viruses; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load

2017
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
    Enfermedades infecciosas y microbiologia clinica, 2017, Volume: 35, Issue:10

    Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation

2017
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.
    The Permanente journal, 2017, Volume: 21

    Topics: Aged; Anemia; Antiviral Agents; California; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Patient Selection; Retrospective Studies; Ribavirin; Sex Factors; Sofosbuvir; Viral Load

2017
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jun-01, Volume: 64, Issue:11

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Sofosbuvir-based regimens against an "easy" villain: HCV genotype 2.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, 04-15, Volume: 74, Issue:8

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load

2017
Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults.
    JAMA internal medicine, 2017, 06-01, Volume: 177, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ill-Housed Persons; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
    British journal of haematology, 2017, Volume: 178, Issue:1

    Topics: Adult; Antiviral Agents; beta-Thalassemia; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Severity of Illness Index; Simeprevir; Sofosbuvir; Valine

2017
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4
    International journal of molecular sciences, 2017, Apr-25, Volume: 18, Issue:5

    Topics: Aged; Antiviral Agents; Asian People; Benzimidazoles; Carrier Proteins; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Intracellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins

2017
Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report.
    Clinical journal of gastroenterology, 2017, Volume: 10, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lichen Planus; Lip; Lip Diseases; Male; Middle Aged; Ribavirin; Sofosbuvir

2017
Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:5

    Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Hong Kong; Humans; Interferon-alpha; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Response to Real life Egyptian experience of efficacy / safety of Simeprevir\\ Sofosbuvir in HCV genotype IV.
    Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome

2017
Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Failure

2017
Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
    AIDS (London, England), 2017, 06-01, Volume: 31, Issue:9

    Topics: Alanine Transaminase; Antiviral Agents; Coinfection; Hepatitis B; Hepatitis E; Hepatitis E virus; Hepatitis, Chronic; HIV Infections; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Viral Load

2017
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2017
Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
    The new microbiologica, 2017, Volume: 40, Issue:3

    Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Immunologic Factors; Prednisolone; Recurrence; Ribavirin; Rituximab; Sofosbuvir; Viral Load

2017
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Advances in medical sciences, 2017, Volume: 62, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Safety; Sofosbuvir; Treatment Outcome

2017
Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017, Volume: 36, Issue:3

    Topics: Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B Core Antigens; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Retrospective Studies; Ribavirin; Risk Factors; Sofosbuvir; Valine

2017
Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, Jun-15, Volume: 74, Issue:12

    Topics: Anticoagulants; Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Ribavirin; Sofosbuvir; Warfarin

2017
Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation

2018
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients.
    Gut and liver, 2017, Sep-15, Volume: 11, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2017
The elderly and direct antiviral agents: Constraint or challenge?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Logistic Models; Male; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2017
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2017, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Young Adult

2017
Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience.
    Journal of medical virology, 2017, Volume: 89, Issue:12

    Topics: Aged; Antiviral Agents; Blood Glucose; Diabetes Mellitus, Type 2; Egypt; Female; Glycated Hemoglobin; Glycemic Index; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir

2017
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2017
Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Scandinavian and Nordic Countries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2017
Direct-acting antivirals for paediatric HCV: we got there.
    Nature reviews. Gastroenterology & hepatology, 2017, 07-26, Volume: 14, Issue:8

    Topics: Adolescent; Antiviral Agents; Child; Genotype; Hepacivirus; Humans; Ribavirin; Sofosbuvir

2017
Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2017, Volume: 37, Issue:8

    Topics: Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Withholding Treatment

2017
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:1

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
    Transplantation, 2017, Volume: 101, Issue:11

    Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Sustained Virologic Response; Tablets; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load

2017
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
    Transplant international : official journal of the European Society for Organ Transplantation, 2017, Volume: 30, Issue:12

    Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome

2017
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    The International journal on drug policy, 2017, Volume: 47

    Topics: Adult; Antiviral Agents; Coinfection; Female; Genotype; Health Services; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Polyethylene Glycols; Program Development; Program Evaluation; Recombinant Proteins; Ribavirin; Risk Factors; Sex Factors; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Ukraine; Young Adult

2017
Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2017, Volume: 27, Issue:7

    Topics: Antiviral Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2017
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
    Antiviral research, 2017, Volume: 146

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Chemokine CXCL10; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Valine; Young Adult

2017
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA exper
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:11

    Topics: Adult; Antiviral Agents; Benzimidazoles; Disease Eradication; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
    Gut and liver, 2017, Sep-15, Volume: 11, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine

2017
Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:9

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response

2017
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Compassionate Use Trials; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Waiting Lists

2018
Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    World journal of gastroenterology, 2017, Aug-28, Volume: 23, Issue:32

    Topics: Adult; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine

2017
Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:12

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Drug Therapy, Combination; Egypt; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; International Normalized Ratio; Male; Middle Aged; Platelet Count; Prospective Studies; Pyrrolidines; Ribavirin; Serum Albumin; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Valine

2017
Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2017, Volume: 18, Issue:3

    Topics: Adult; Age Factors; Antiviral Agents; Cold Ischemia; Drug Therapy, Combination; Female; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Warm Ischemia; Young Adult

2017
Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult

2017
Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
    Archives of virology, 2018, Volume: 163, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir

2018
Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2.
    Digestive diseases (Basel, Switzerland), 2017, Volume: 35, Issue:6

    Topics: alpha-Fetoproteins; Antiviral Agents; Biomarkers, Tumor; Bone Morphogenetic Protein 7; Carcinoma, Hepatocellular; Connective Tissue Growth Factor; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2017
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Value in health regional issues, 2017, Volume: 13

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Egypt; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Models, Statistical; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Uridine Monophosphate; Valine

2017
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    The Journal of antimicrobial chemotherapy, 2017, 10-01, Volume: 72, Issue:10

    Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2017
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2018
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load

2018
Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Genotype; Heart Transplantation; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Sofosbuvir

2018
Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:6(Suppleme

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Sorafenib; Sustained Virologic Response; Treatment Outcome

2017
Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
    Clinical transplantation, 2018, Volume: 32, Issue:2

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine

2018
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:7

    Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2018
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:3

    Topics: Antiviral Agents; Australia; Carbamates; Compassionate Use Trials; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Survival Analysis; Treatment Outcome; Valine

2018
Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.
    Histopathology, 2018, Volume: 72, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Inflammation; Liver Transplantation; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate

2018
Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens.
    The Journal of infectious diseases, 2018, 03-13, Volume: 217, Issue:7

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Opiate Substitution Treatment; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
    Antiviral therapy, 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Vietnam; Viral Load

2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
    Journal of medical virology, 2018, Volume: 90, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
    Archives of virology, 2018, Volume: 163, Issue:4

    Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine

2018
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
    Internal medicine (Tokyo, Japan), 2018, Jun-01, Volume: 57, Issue:11

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Diabetes Complications; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Uridine Monophosphate

2018
Sustained improvement of psoriasis associated with HCV after virologic response to sofosbuvir/ribavirin.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2017, Volume: 18, Issue:4

    Topics: Adolescent; Antiviral Agents; Hepatitis C; Humans; Male; Psoriasis; Ribavirin; Sofosbuvir

2017
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
    Journal of medical virology, 2018, Volume: 90, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Carbamates; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2018
Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2018, Volume: 38, Issue:2

    Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Valine

2018
Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2018, Volume: 31, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Uridine Monophosphate

2018
A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan.
    Infectious diseases of poverty, 2018, Feb-11, Volume: 7, Issue:1

    Topics: Antiviral Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Phylogeny; Polymorphism, Genetic; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2018
Complete Response of Diffuse Large B Cell Lymphoma After Direct-Acting Antiviral Therapy for Hepatitis C Virus.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019, Volume: 17, Issue:5

    Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Radiography, Abdominal; Ribavirin; Sofosbuvir; Treatment Outcome

2019
Editorial: sofosbuvir plus daclatasvir for the treatment of hepatitis C-can one size fit all?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:6

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
EFFECTIVE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS WITH DIRECT ACTING ANTIVIRALS IN PRISONS SYSTEM.
    Georgian medical news, 2018, Issue:274

    Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; gamma-Glutamyltransferase; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Prisoners; Prisons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2018
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:7

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation

2018
Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
    Antiviral therapy, 2018, Volume: 23, Issue:5

    Topics: Antiviral Agents; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Heart Transplantation; Hepatitis E; Hepatitis E virus; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure

2018
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.
    Clinics and research in hepatology and gastroenterology, 2018, Volume: 42, Issue:4

    Topics: Aged; Antibodies; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Peptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Seroepidemiologic Studies; Sofosbuvir; Valine; Viral Load

2018
Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2018, Volume: 38, Issue:3

    Topics: Antiviral Agents; Female; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Microbial Sensitivity Tests; Middle Aged; Ribavirin; Sofosbuvir

2018
Treatment of HCV in the Department of Corrections in the Era of Oral Medications.
    Journal of correctional health care : the official journal of the National Commission on Correctional Health Care, 2018, Volume: 24, Issue:2

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prisons; Ribavirin; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2018
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:10

    Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Esophageal and Gastric Varices; Fatigue; Female; Fluorenes; Gastrointestinal Hemorrhage; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nausea; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2018
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    The International journal of artificial organs, 2018, Volume: 41, Issue:7

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine

2018
Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cross Infection; Disease Outbreaks; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors

2018
Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus.
    World journal of gastroenterology, 2018, Apr-07, Volume: 24, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Bullous pemphigoid associated with chronic hepatitis C virus infection in a hepatitis B virus endemic area: A case report.
    Medicine, 2018, Volume: 97, Issue:15

    Topics: Administration, Oral; Aged; Antibodies, Viral; Antiviral Agents; Diagnosis, Differential; DNA, Viral; Glucocorticoids; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Male; Methylprednisolone; Pemphigoid, Bullous; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures.
    SAR and QSAR in environmental research, 2018, Volume: 29, Issue:5

    Topics: Antiviral Agents; Drug Design; Models, Molecular; Molecular Docking Simulation; Nucleosides; Nucleotides; Ribavirin; RNA-Dependent RNA Polymerase; Sofosbuvir; Tenofovir; Zika Virus

2018
Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal.
    Transplantation proceedings, 2018, Volume: 50, Issue:3

    Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Portugal; Postoperative Complications; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2018
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
    Transplantation proceedings, 2018, Volume: 50, Issue:3

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
    Hepatology international, 2018, Volume: 12, Issue:4

    Topics: Administration, Oral; Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2018
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult

2018
Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
    The Annals of pharmacotherapy, 2018, Volume: 52, Issue:11

    Topics: Antiviral Agents; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Pregnancy; Ribavirin; Sofosbuvir; Time Factors

2018
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Blood Glucose; Carbamates; Diabetes Mellitus; Drug Therapy, Combination; Female; Glycated Hemoglobin; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2018
Economic evaluation of Zepatier for the management of HCV in the Italian scenario.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2018, Volume: 19, Issue:9

    Topics: Antiviral Agents; Benzofurans; Cost of Illness; Cost-Benefit Analysis; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Italy; Markov Chains; Quality-Adjusted Life Years; Quinoxalines; Ribavirin; Sofosbuvir

2018
Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus.
    Annals of internal medicine, 2018, 09-04, Volume: 169, Issue:5

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Lupus Nephritis; Nephrotic Syndrome; Prednisolone; Remission Induction; Ribavirin; Sofosbuvir; Tacrolimus

2018
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:12

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine

2018
Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:8

    Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Hepatitis C; Humans; Imidazoles; Incidence; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine

2018
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis.
    The Journal of infection, 2018, Volume: 76, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate

2018
Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
    The American journal of the medical sciences, 2018, Volume: 355, Issue:5

    Topics: Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2018
Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.
    Hepatology international, 2018, Volume: 12, Issue:4

    Topics: Adult; Antiviral Agents; Carbamates; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
    Internal medicine (Tokyo, Japan), 2018, Oct-01, Volume: 57, Issue:19

    Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine

2018
Comparative study of six sequential spectrophotometric methods for quantification and separation of ribavirin, sofosbuvir and daclatasvir: An application on Laboratory prepared mixture, pharmaceutical preparations, spiked human urine, spiked human plasma,
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Sep-05, Volume: 202

    Topics: Carbamates; Humans; Imidazoles; Limit of Detection; Pharmaceutical Preparations; Pyrrolidines; Reproducibility of Results; Ribavirin; Sofosbuvir; Solubility; Spectrophotometry; Valine

2018
[Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2018, Mar-20, Volume: 26, Issue:3

    Topics: Adolescent; Aged; Antiviral Agents; China; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2018
Localized scleroderma occurring after treatment of chronic hepatitis C with sofosbuvir and ribavirin.
    The Journal of dermatology, 2019, Volume: 46, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Scleroderma, Localized; Skin; Sofosbuvir; Treatment Outcome

2019
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
    Clinical and molecular hepatology, 2018, Volume: 24, Issue:3

    Topics: Aged; Anemia; Antiviral Agents; Dizziness; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2018
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation.
    PloS one, 2018, Volume: 13, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Ritonavir; Sofosbuvir; Treatment Outcome

2018
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir

2018
Letter: concordance of SVR4 and SVR12 following direct-acting anti-viral treatment in Egypt.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Antiviral Agents; Carbamates; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2018
Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir

2018
Editorial: retreatment of DAA-failures-no problem at all?
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Retreatment; Ribavirin; Simeprevir; Sofosbuvir

2018
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C.
    Journal of clinical gastroenterology, 2019, Volume: 53, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult

2019
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Journal of gastrointestinal and liver diseases : JGLD, 2018, Volume: 27, Issue:2

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine

2018
Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a.
    The Journal of general virology, 2018, Volume: 99, Issue:8

    Topics: Antiviral Agents; Cell Line; Cloning, Molecular; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Mutagenesis; Mutation; Nucleic Acid Amplification Techniques; Open Reading Frames; Ribavirin; RNA, Viral; Sofosbuvir; Viral Proteins

2018
Autochthonous acute hepatitis E: treatment with sofosbuvir and ribavirin.
    Infection, 2018, Volume: 46, Issue:5

    Topics: Acute-On-Chronic Liver Failure; Biomarkers; Coinfection; Drug Therapy, Combination; Fatal Outcome; Hepatitis E; Humans; Liver Function Tests; Male; Middle Aged; Ribavirin; Shock, Septic; Sofosbuvir; Treatment Outcome; Viral Load

2018
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:7

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medicaid; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate; Viral Load

2018
Direct-acting antiviral drugs are triggers for psoriasis: report of three cases.
    International journal of dermatology, 2018, Volume: 57, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Psoriasis; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Symptom Flare Up; Valine

2018
Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study.
    Medicine, 2018, Volume: 97, Issue:27

    Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.
    Current drug safety, 2018, Volume: 13, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Male; Middle Aged; Pharmacovigilance; Prospective Studies; Pyrrolidines; Ribavirin; Severity of Illness Index; Sofosbuvir; Valine

2018
Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
    Infectious disorders drug targets, 2020, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Carbamates; Case-Control Studies; Drug Combinations; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2020
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:11

    Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Registries; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load

2018
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PloS one, 2018, Volume: 13, Issue:7

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Polymorphism, Genetic; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2018
High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2018, Volume: 75

    Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Community Health Centers; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2018
High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:10

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load

2018
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
    Indian journal of pediatrics, 2019, Volume: 86, Issue:2

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2019
[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
    Anales de pediatria, 2019, Volume: 90, Issue:3

    Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load

2019
Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    Journal of medical virology, 2019, Volume: 91, Issue:2

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2019
Findings from a large Asian chronic hepatitis C real-life study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:12

    Topics: Adult; Antiviral Agents; Asia; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Annals of hepatology, 2018, Aug-24, Volume: 17, Issue:5

    Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2018
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
    Clinical and molecular hepatology, 2018, Volume: 24, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir

2018
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?
    Gastroenterology, 2018, Volume: 155, Issue:4

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
    Scientific reports, 2018, 09-12, Volume: 8, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Taiwan

2018
Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective.
    Journal of pediatric gastroenterology and nutrition, 2019, Volume: 68, Issue:1

    Topics: Adolescent; Antiviral Agents; Carbamates; Child; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Male; Program Evaluation; Public Health; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2019
Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study.
    Medicine, 2018, Volume: 97, Issue:38

    Topics: Adult; Antiviral Agents; China; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load; Young Adult

2018
Eradication of HCV in Renal Transplant Recipients and Its Effects on Quality of Life.
    BioMed research international, 2018, Volume: 2018

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Italy; Kidney Transplantation; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome

2018
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Biomarkers; Carbamates; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Prothrombin Time; Pyrrolidines; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine

2019
Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
    Virology journal, 2018, 10-01, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Asian People; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2018
Hand-foot syndrome due to hepatitis C therapy.
    Revista da Associacao Medica Brasileira (1992), 2018, Volume: 64, Issue:5

    Topics: Antiviral Agents; Hand-Foot Syndrome; Hepatitis C; Humans; Interferons; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir

2018
Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2019, Volume: 118, Issue:5

    Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Valine

2019
No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity.
    Internal medicine (Tokyo, Japan), 2019, Feb-15, Volume: 58, Issue:4

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Geography; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
    Expert review of pharmacoeconomics & outcomes research, 2019, Volume: 19, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Markov Chains; Pyrrolidines; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate; Valine

2019
Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Carbamates; China; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2019
Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
    Antiviral therapy, 2019, Volume: 24, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2019
Predictive value of IL-28B rs12979860 variants for peg-IFN, sofosbuvir plus ribavirin treatment of HCV infection in Pakistani population.
    Personalized medicine, 2018, Volume: 15, Issue:6

    Topics: Adult; Antiviral Agents; Biomarkers, Pharmacological; Cross-Sectional Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Pakistan; Polyethylene Glycols; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Direct acting antiviral-based treatment of hepatitis C virus infection among people who inject drugs in Georgia: A prospective cohort study.
    The International journal on drug policy, 2018, Volume: 62

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug Users; Female; Genotype; Georgia; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous

2018
Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis.
    Digestive diseases and sciences, 2019, Volume: 64, Issue:2

    Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Carbamates; Female; gamma-Globulins; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Imidazoles; Liver; Liver Cirrhosis; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Serum Albumin; Sofosbuvir; Valine; Viral Load

2019
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2019
The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2018, Oct-25, Volume: 72, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Dyspepsia; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2018
Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:4

    Topics: Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Ribavirin; Sofosbuvir; Treatment Outcome

2019
Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
    Journal of hepatology, 2019, Volume: 70, Issue:3

    Topics: Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2019
[Treatment of Hepatitis C: State of the Art 2018].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:24

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response

2018
Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2018, Volume: 72, Issue:5

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load

2018
Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting?
    Journal of digestive diseases, 2019, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult

2019
Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis E; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Ribavirin; Sofosbuvir

2019
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:5

    Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine

2019
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome; Uridine Monophosphate

2018
Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    Journal of gastroenterology, 2019, Volume: 54, Issue:3

    Topics: Carbamates; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir

2019
Th17 and IL-17 as Predictors of Hepatic Inflammation in Patients with Chronic Hepatitis C Virus Infection and Treated With Direct Antiviral Therapy.
    The Egyptian journal of immunology, 2018, Volume: 25, Issue:2

    Topics: Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Inflammation; Interleukin-17; Ribavirin; Sofosbuvir; Sustained Virologic Response; Th17 Cells; Treatment Outcome

2018
Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2018, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Indonesia; Male; Medically Underserved Area; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult

2018
Anatomical and Functional Retinal Complications of Combined Sofosbuvir and Ribavirin Therapy in Patients With Chronic Hepatitis C Virus.
    Ophthalmic surgery, lasers & imaging retina, 2019, 01-01, Volume: 50, Issue:1

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Retina; Ribavirin; Sofosbuvir; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Young Adult

2019
Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2019, Volume: 39, Issue:2

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2019
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
    Scientific reports, 2019, 01-24, Volume: 9, Issue:1

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine

2019
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Hepatology international, 2019, Volume: 13, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response

2019
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
    Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:9

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine

2019
Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
    Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Costs; Drug Therapy, Combination; Female; Fluorenes; Health Care Costs; Hepatitis C, Chronic; Humans; Insurance, Health; Interferon-alpha; Male; Medicare; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Young Adult

2019
Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:3

    Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Tacrolimus; Young Adult

2019
No Clear Evidence for an Effect of Sofosbuvir Against Hepatitis E Virus in Organ Transplant Patients.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:4

    Topics: Antiviral Agents; Hepatitis E; Hepatitis E virus; Humans; Kidney Transplantation; Ribavirin; Sofosbuvir

2019
Reply.
    Hepatology (Baltimore, Md.), 2019, Volume: 69, Issue:4

    Topics: Hepatitis E; Humans; Kidney Transplantation; Ribavirin; Sofosbuvir

2019
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate

2019
Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
    Hepatology international, 2019, Volume: 13, Issue:2

    Topics: Adult; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Patient Selection; Pyrrolidines; Quality of Life; Ribavirin; RNA, Viral; Severity of Illness Index; Sofosbuvir; Survival Rate; Sustained Virologic Response; Ultrasonography; Valine

2019
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2019, Volume: 32, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2019
Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2019, Volume: 17, Issue:Suppl 1

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pakistan; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load

2019
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.
    Clinical and molecular hepatology, 2019, Volume: 25, Issue:1

    Topics: Aged; Anemia, Hemolytic; Carnitine; Drug Therapy, Combination; Female; Hepatitis C; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome

2019
The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy.
    Research in social & administrative pharmacy : RSAP, 2020, Volume: 16, Issue:1

    Topics: Antiviral Agents; Carbamates; Community Pharmacy Services; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Medication Adherence; Middle Aged; Pharmacists; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2020
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2.
    The Korean journal of internal medicine, 2021, Volume: 36, Issue:3

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissoluti
    Drug development and industrial pharmacy, 2019, Volume: 45, Issue:7

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Imidazoles; Limit of Detection; Pyrrolidines; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Sofosbuvir; Solubility; Valine

2019
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    PloS one, 2019, Volume: 14, Issue:4

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult

2019
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.
    Acta medica portuguesa, 2019, Mar-29, Volume: 32, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Portugal; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult

2019
High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
    Journal of medical virology, 2022, Volume: 94, Issue:2

    Topics: Adult; Anemia; Anilides; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2022
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Gut and liver, 2020, 05-15, Volume: 14, Issue:3

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Direct-acting antivirals and visceral leishmaniasis: a case report.
    BMC infectious diseases, 2019, Apr-18, Volume: 19, Issue:1

    Topics: Aged; Amphotericin B; Antiprotozoal Agents; Antiviral Agents; Coinfection; Hepatitis C, Chronic; Humans; Leishmania infantum; Leishmaniasis, Visceral; Male; Ribavirin; Sofosbuvir

2019
Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient.
    Journal of hepatology, 2019, Volume: 71, Issue:1

    Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis E; Hepatitis E virus; Humans; Immunosuppressive Agents; Male; Multiple Organ Failure; Organ Transplantation; Ribavirin; Sofosbuvir; Treatment Failure

2019
Validated RP-HPLC Method for Simultaneous Determination of Ribavirin, Sofosbuvir and Daclatasvir in Human Plasma: A Treatment Protocol Administered to HCV Patients in Egypt.
    Journal of chromatographic science, 2019, Aug-01, Volume: 57, Issue:7

    Topics: Carbamates; Chromatography, High Pressure Liquid; Egypt; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Ribavirin; Sofosbuvir; Valine

2019
Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis.
    The Korean journal of internal medicine, 2020, Volume: 35, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2020
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Myanmar; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine

2019
Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report.
    BMC gastroenterology, 2019, May-24, Volume: 19, Issue:1

    Topics: Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Hepatitis E; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Ribavirin; Sofosbuvir

2019
B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Brazil; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult

2019
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
    Virology journal, 2019, 06-03, Volume: 16, Issue:1

    Topics: Adult; Antiviral Agents; Asian People; China; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:10

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Phylogeny; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins

2019
Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2019, Volume: 39, Issue:9

    Topics: Antiviral Agents; Carbamates; Egypt; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2019
Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
    BMJ open, 2019, 06-19, Volume: 9, Issue:6

    Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology (Baltimore, Md.), 2020, Volume: 71, Issue:1

    Topics: Antiviral Agents; Child; Child, Preschool; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report.
    Journal of infection and public health, 2020, Volume: 13, Issue:1

    Topics: Aged; Antiviral Agents; Asthma; Carbamates; Coinfection; Diabetes Complications; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis B; Hepatitis C, Chronic; Hepatitis E; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tenofovir; Treatment Outcome; Valine; Viral Load

2020
Follow-up Results of
    Anticancer research, 2019, Volume: 39, Issue:7

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2019
Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation.
    Journal of the Chinese Medical Association : JCMA, 2019, Volume: 82, Issue:7

    Topics: Acute Disease; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Liver Failure; Male; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine

2019
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Journal of hepatology, 2019, Volume: 71, Issue:5

    Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins

2019
Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies.
    Archives of psychiatric nursing, 2019, Volume: 33, Issue:4

    Topics: Adult; Anemia; Antiviral Agents; Comorbidity; Delivery of Health Care, Integrated; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Interprofessional Relations; Male; Middle Aged; Personality Disorders; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Ribavirin; Sofosbuvir; Substance-Related Disorders

2019
Effect of Combined HCV Therapy on Natural Killer Cell Activity.
    The Egyptian journal of immunology, 2019, Volume: 26, Issue:1

    Topics: Adult; Antiviral Agents; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 3; Ribavirin; Sofosbuvir; Sustained Virologic Response

2019
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
    Journal of medical virology, 2019, Volume: 91, Issue:12

    Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tuberculosis; Valine

2019
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
    Medicine, 2019, Volume: 98, Issue:30

    Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2019
Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
    Journal of the Chinese Medical Association : JCMA, 2019, Volume: 82, Issue:9

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Valine

2019
[Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, 06-20, Volume: 27, Issue:6

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2019
Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients.
    Journal of medical virology, 2019, Volume: 91, Issue:12

    Topics: Adult; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; MicroRNAs; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Transforming Growth Factor beta; Treatment Outcome; Valine; Viral Load

2019
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
    European journal of clinical pharmacology, 2019, Volume: 75, Issue:11

    Topics: Aged; Anemia; Antiviral Agents; Carbamates; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Tacrolimus; Valine

2019
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2019, Volume: 52, Issue:8

    Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load

2019
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
    PloS one, 2019, Volume: 14, Issue:8

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins

2019
Treatment of hepatitis C in two paediatric patients using sofosbuvir during haematopoietic stem cell transplantation.
    Antiviral therapy, 2019, Volume: 24, Issue:8

    Topics: Antiviral Agents; Child; Child, Preschool; Dasatinib; Female; Hematopoietic Stem Cell Transplantation; Hepatitis C; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Viral Load

2019
Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:3

    Topics: Antiviral Agents; Brazil; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine

2020
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    Journal of medical virology, 2020, Volume: 92, Issue:2

    Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine

2020
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11

    Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine

2019
Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
    The new microbiologica, 2019, Volume: 42, Issue:4

    Topics: 2-Naphthylamine; Antiviral Agents; Biomarkers, Pharmacological; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil

2019
Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:3

    Topics: Age Factors; Antiviral Agents; Benzimidazoles; British Columbia; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Lost to Follow-Up; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
[QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2019, Volume: 139, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Surveys and Questionnaires

2019
Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retreatment; Ribavirin; Sofosbuvir; Sustained Virologic Response

2020
Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
    Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Brazil; Carbamates; Drug Therapy, Combination; Fatigue; Female; Headache; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidines; Ribavirin; Risk Factors; Sofosbuvir; Valine

2019
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 02-07, Volume: 114, Issue:3

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
    Advances in therapy, 2020, Volume: 37, Issue:1

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2020
The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 121

    Topics: Carbamates; Drug Therapy, Combination; Egypt; Endpoint Determination; Gene Frequency; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Logistic Models; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy.
    Gastroenterologia y hepatologia, 2020, Volume: 43, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Burkitt Lymphoma; Common Variable Immunodeficiency; Drug Therapy, Combination; Fatal Outcome; Focal Nodular Hyperplasia; Hepatitis E; Hepatitis E virus; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Kidney Transplantation; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir

2020
Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    BMC infectious diseases, 2020, Jan-10, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Lost to Follow-Up; Male; Middle Aged; National Health Programs; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Young Adult

2020
Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 04-08, Volume: 114, Issue:4

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro.
    Antiviral research, 2020, Volume: 175

    Topics: A549 Cells; Antiviral Agents; Cell Line; Drug Resistance, Viral; Hepatocytes; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Mutation; Neurons; Ribavirin; Sofosbuvir; Virus Replication; West Nile virus

2020
[Progress of antiviral therapy for hepatitis C virus-related decompensated cirrhosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019, Dec-20, Volume: 27, Issue:12

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Ribavirin; Sofosbuvir; Treatment Outcome

2019
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:4

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Italy; Male; Middle Aged; Pyrrolidines; Regression Analysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2020
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:4

    Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.
    Gut and liver, 2020, 11-15, Volume: 14, Issue:6

    Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Republic of Korea; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load

2020
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
    Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020

    Topics: Acute Kidney Injury; Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Egypt; Female; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney; Lipocalin-2; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Valine

2020
Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals
.
    International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:5

    Topics: Antiviral Agents; Carbamates; Cote d'Ivoire; Cross-Sectional Studies; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hospitals, University; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Thailand; Time Factors; Treatment Outcome; Uridine Monophosphate

2020
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
    Life sciences, 2020, May-01, Volume: 248

    Topics: Adenosine Monophosphate; Alanine; Alphacoronavirus; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Catalytic Domain; Computational Biology; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Guanosine Monophosphate; Guanosine Triphosphate; Humans; Molecular Docking Simulation; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Ribavirin; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Sofosbuvir; Thermodynamics; Uridine Triphosphate; Viral Proteins

2020
Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
    BMC gastroenterology, 2020, Mar-05, Volume: 20, Issue:1

    Topics: Adiponectin; Aged; Alanine Transaminase; Benzimidazoles; Blood Glucose; Carbamates; Cholesterol; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Insulin; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins

2020
Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2020, Volume: 31, Issue:2

    Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Azerbaijan; Cyclopropanes; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine

2020
Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
    BMC gastroenterology, 2020, Apr-06, Volume: 20, Issue:1

    Topics: Adult; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Pakistan; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Tomography, X-Ray Computed; Valine

2020
Micellar high performance liquid chromatographic method for separation and validation of two anti-hepatitis C- virus drugs in pure form, human plasma and human urine.
    Annales pharmaceutiques francaises, 2020, Volume: 78, Issue:3

    Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Cost-Benefit Analysis; Hepatitis C; Humans; Limit of Detection; Reproducibility of Results; Ribavirin; Sofosbuvir; Solubility

2020
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:e1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection.
    The Pediatric infectious disease journal, 2020, Volume: 39, Issue:6

    Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; China; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Markov Chains; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; United States

2020
High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:9

    Topics: Antiviral Agents; Cambodia; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
    Zeitschrift fur Gastroenterologie, 2020, Volume: 58, Issue:5

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Middle Aged; Neoplasm Recurrence, Local; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 06-02, Volume: 117, Issue:22

    Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine

2020
Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    PloS one, 2020, Volume: 15, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Vietnam; Viral Load

2020
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult

2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:8

    Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2020
Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients.
    Transplant infectious disease : an official journal of the Transplantation Society, 2020, Volume: 22, Issue:5

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir

2020
The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2020, Volume: 31, Issue:5

    Topics: Aged; Anilides; Antiviral Agents; Benzimidazoles; Blood Glucose; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Lactams, Macrocyclic; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Triglycerides; Valine

2020
HCV eradication in chronic kidney disease: ready for prime time?
    The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:10

    Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir

2020
Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
    Immunologic research, 2020, Volume: 68, Issue:3

    Topics: Aged; Antibodies, Antinuclear; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Fluorescent Antibody Technique, Indirect; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine

2020
M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
    World journal of gastroenterology, 2020, Jun-07, Volume: 26, Issue:21

    Topics: Adult; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Biomarkers, Tumor; Carbamates; Drug Combinations; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Glycosylation; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; ROC Curve; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2020
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan

2020
Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:11

    Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Prospective Studies; Retreatment; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Modeling based response guided therapy in subjects with recent hepatitis C infection.
    Antiviral research, 2020, Volume: 180

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Duration of Therapy; Female; Hepatitis C; Humans; Male; Middle Aged; Models, Theoretical; Predictive Value of Tests; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Young Adult

2020
Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication.
    The Kaohsiung journal of medical sciences, 2020, Volume: 36, Issue:11

    Topics: Aged; Antiviral Agents; Carbamates; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Risk; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Triglycerides; Valine

2020
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.
    Clinical journal of gastroenterology, 2020, Volume: 13, Issue:6

    Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:11

    Topics: Africa South of the Sahara; Antiviral Agents; Cote d'Ivoire; Hepatitis C, Chronic; Humans; Liver Neoplasms; Ribavirin; Sofosbuvir

2020
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir.
    European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:12

    Topics: Antiviral Agents; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2021
A decrease in hepatitis C virus RNA to undetectable levels in chronic hepatitis C patients after PegIFNα + RVB or sofosbuvir + NS5A inhibitor treatment is associated with decreased insulin resistance and persistent oxidative stress.
    Archives of virology, 2020, Volume: 165, Issue:12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insulin Resistance; Interferon-alpha; Male; Middle Aged; Oxidative Stress; Pilot Projects; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins

2020
Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2021, Volume: 120, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome

2021
Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
    Journal of gastrointestinal and liver diseases : JGLD, 2020, Sep-09, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Romania; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load

2020
The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents.
    Expert review of gastroenterology & hepatology, 2021, Volume: 15, Issue:1

    Topics: Adult; Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lipid Metabolism; Lipids; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Valine

2021
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PloS one, 2020, Volume: 15, Issue:10

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir

2020
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:2

    Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Infant, Newborn; Liver Cirrhosis; Liver Neoplasms; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
    Journal of acquired immune deficiency syndromes (1999), 2021, 02-01, Volume: 86, Issue:2

    Topics: Anilides; Antiviral Agents; Benzimidazoles; Coinfection; Cyclopropanes; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2021
Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2020, Volume: 86

    Topics: Alleles; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interleukins; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir

2020
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    The Kaohsiung journal of medical sciences, 2021, Volume: 37, Issue:4

    Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine

2021
Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients.
    Virus research, 2021, 01-15, Volume: 292

    Topics: alpha-Fetoproteins; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Haplotypes; Hepatitis C, Chronic; Humans; Interferon-alpha; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, Interleukin-17; Recombinant Proteins; Ribavirin; Sofosbuvir

2021
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.
    Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020

    Topics: Antiviral Agents; Child; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
    European journal of gastroenterology & hepatology, 2020, Volume: 32, Issue:8

    Topics: Antiviral Agents; Carbamates; Child; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Male; Morbidity; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2020
Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort.
    Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:5

    Topics: Adult; Carbamates; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:11

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Renal Dialysis; Ribavirin; Sofosbuvir; Treatment Outcome

2020
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2021, Volume: 22, Issue:1

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome

2021
Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme.
    International journal of clinical pharmacy, 2021, Volume: 43, Issue:4

    Topics: Antiviral Agents; Developing Countries; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir

2021
Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
    Journal of gastrointestinal and liver diseases : JGLD, 2020, 12-13, Volume: 29, Issue:4

    Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Ribavirin; Sofosbuvir

2020
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
    Gut, 2022, Volume: 71, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Young Adult

2022
Sofosbuvir plus ribavirin combination regimen boost liver functions and antioxidant profile in hepatitis C virus patients.
    Microbial pathogenesis, 2021, Volume: 150

    Topics: Antioxidants; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
    Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:5

    Topics: Anti-Retroviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Carbamazepine; Cell Membrane; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir

2021
[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021, Jan-20, Volume: 29, Issue:1

    Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; China; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Ribavirin Improves NK Cell IFNγ Response During Sofosbuvir-based DAA Therapy in HCV-infected Liver Transplant Recipients.
    Transplantation, 2021, 10-01, Volume: 105, Issue:10

    Topics: Antiviral Agents; Case-Control Studies; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-gamma; Killer Cells, Natural; Liver Transplantation; Phosphorylation; Ribavirin; Sofosbuvir; STAT1 Transcription Factor; STAT4 Transcription Factor; Time Factors; Treatment Outcome

2021
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    Journal of hepatology, 2021, Volume: 75, Issue:1

    Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides

2021
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Journal of medical virology, 2021, Volume: 93, Issue:8

    Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Mutation; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Nonstructural Proteins

2021
Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study.
    Medicine, 2021, Mar-26, Volume: 100, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
    Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:4

    Topics: Adolescent; Adult; Aged; Antiviral Agents; Black People; Carbamates; Drug Therapy, Combination; Egypt; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine; Young Adult

2021
Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    Journal of hepatology, 2021, Volume: 75, Issue:1

    Topics: Aminoisobutyric Acids; Benzimidazoles; Cyclopropanes; Hepacivirus; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides

2021
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
    BMC infectious diseases, 2021, Apr-26, Volume: 21, Issue:1

    Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2021
Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2021
Single-pill sofosbuvir and daclatasvir for treating hepatis C in patients co-infected with human immunodeficiency virus.
    International journal of clinical practice, 2021, Volume: 75, Issue:8

    Topics: Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Imidazoles; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine

2021
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2021, Volume: 32, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey

2021
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
    Internal medicine (Tokyo, Japan), 2021, Nov-15, Volume: 60, Issue:22

    Topics: Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Retrospective Studies; Ribavirin; Sofosbuvir

2021
Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Medication Therapy Management; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2021, Volume: 30, Issue:12

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Infant; Quality of Life; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
    Internal medicine (Tokyo, Japan), 2021, Nov-01, Volume: 60, Issue:21

    Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2021
Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China.
    Scientific reports, 2021, 05-28, Volume: 11, Issue:1

    Topics: Adult; Antiviral Agents; China; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Ribavirin; Rural Population; Sofosbuvir; Sustained Virologic Response

2021
Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study.
    Journal of Korean medical science, 2021, May-31, Volume: 36, Issue:21

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.
    Le infezioni in medicina, 2021, Jun-01, Volume: 29, Issue:2

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Italy; Macrocyclic Compounds; Prevalence; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides

2021
Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
    Medicine, 2021, Jun-18, Volume: 100, Issue:24

    Topics: Adult; Antiviral Agents; China; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2021
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
    Pharmacology research & perspectives, 2021, Volume: 9, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Valine

2021
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.
    Clinical and molecular hepatology, 2021, Volume: 27, Issue:4

    Topics: Antiviral Agents; Carbamates; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2021
Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line.
    Anais da Academia Brasileira de Ciencias, 2021, Volume: 93, Issue:4

    Topics: Antiviral Agents; Cell Line; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Simeprevir; Sofosbuvir

2021
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
    Zeitschrift fur Gastroenterologie, 2022, Volume: 60, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome

2022
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Oct-01, Volume: 22, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Ascites; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interleukin-10; Liver Cirrhosis; Liver Neoplasms; Lymphadenitis; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Splenomegaly; Valine

2021
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
    Microbial pathogenesis, 2022, Volume: 162

    Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Immunity, Innate; Nerve Tissue Proteins; Ribavirin; Sofosbuvir; Treatment Outcome

2022
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021, Dec-20, Volume: 29, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2021
Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAAs?
    Journal of hepatology, 2022, Volume: 77, Issue:1

    Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Sustained Virologic Response

2022
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:4

    Topics: Antiviral Agents; Canada; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome

2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:8

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate

2022
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71(Suppl 8), Issue:12

    Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate

2021
High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection.
    Antiviral research, 2022, Volume: 199

    Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis E; Hepatitis E virus; Humans; Rabbits; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis.
    Journal of the Chinese Medical Association : JCMA, 2022, 05-01, Volume: 85, Issue:5

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study.
    Canadian journal of gastroenterology & hepatology, 2022, Volume: 2022

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2022
[Efficacy and tolerance of direct-acting antiviral drugs for the treatment of hepatitis C in Joseph Raseta Befelatanana Teaching Hospital in Antananarivo, Madagascar].
    Medecine tropicale et sante internationale, 2021, 09-30, Volume: 1, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Madagascar; Retrospective Studies; Ribavirin; Sofosbuvir

2021
Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol.
    Scientific reports, 2022, 06-15, Volume: 12, Issue:1

    Topics: Antiviral Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome

2022
Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:10

    Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Turkey

2022
Dual versus triple therapy in treatment of hepatitis C virus (HCV).
    Irish journal of medical science, 2023, Volume: 192, Issue:3

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
    Internal medicine (Tokyo, Japan), 2023, May-15, Volume: 62, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2022, Volume: 64

    Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Treatment Outcome

2022
Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort.
    Medicine, 2022, Sep-02, Volume: 101, Issue:35

    Topics: Aged; Antiviral Agents; Brazil; Female; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome

2022
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Sep-01, Volume: 23, Issue:9

    Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Fibrosis; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Leukocytes, Mononuclear; Pyrrolidines; Ribavirin; RNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine

2022
Effects of the 5'-Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS-CoV-2.
    ChemMedChem, 2022, 12-05, Volume: 17, Issue:23

    Topics: Antiviral Agents; COVID-19; Cytidine; Escherichia coli; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Vidarabine

2022
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
    Internal medicine (Tokyo, Japan), 2023, Sep-01, Volume: 62, Issue:17

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir

2023
Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
    BMC gastroenterology, 2022, Dec-03, Volume: 22, Issue:1

    Topics: Antiviral Agents; Circulating MicroRNA; Egypt; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; MicroRNAs; Ribavirin; Sofosbuvir

2022
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
    eLife, 2023, Jan-09, Volume: 12

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Pilot Projects; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.
    Clinical and molecular hepatology, 2023, Volume: 29, Issue:2

    Topics: Antiviral Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins

2023
[A case of chronic hepatitis C treated with sofosbuvir/velpatasvir combined with ribavirin among 3-year-old children with low body weight].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023, Feb-20, Volume: 31, Issue:2

    Topics: Antiviral Agents; Body Weight; Child, Preschool; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2023, Volume: 43, Issue:9

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interleukins; Liver Cirrhosis; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2023, Volume: 131, Issue:8

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response

2023
Fitness-Dependent, Mild Mutagenic Activity of Sofosbuvir for Hepatitis C Virus.
    Antimicrobial agents and chemotherapy, 2023, 07-18, Volume: 67, Issue:7

    Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Mutagens; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Spectroscopic study to verify the anti-hepatitis C virus (HCV) treatment through a delivery system of the sofosbuvir drug on chitosan and pycnogenol nanoparticles surface.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2023, Dec-05, Volume: 302

    Topics: Animals; Antiviral Agents; Chitosan; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Mice; Pharmaceutical Preparations; Ribavirin; Sofosbuvir; Spectrum Analysis

2023
Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
    Medicine, 2023, Jul-14, Volume: 102, Issue:28

    Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukin-12; Interleukins; Polymorphism, Single Nucleotide; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
    Viruses, 2023, 09-29, Volume: 15, Issue:10

    Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome

2023
Usefulness Of Sofosbuvir And Daclatasvir Combination In The Treatment Of HCV Infection In Childhood Cancer Patients: Experience From A Tertiary Care Hospital.
    JPMA. The Journal of the Pakistan Medical Association, 2023, Volume: 73, Issue:11

    Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Neoplasms; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Treatment Outcome

2023
Effectiveness of generic sofosbuvir in the treatment of chronic hepatitis C virus infection in Saudi patients.
    Saudi medical journal, 2023, Volume: 44, Issue:12

    Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Drugs, Generic; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Treatment Outcome

2023